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BIS-PYRIDINO CONTAINING COMPOUNDS 
FOR THE USE IN THE TREATMENT OF CNS 
PATHOLOGIES 
RELATED APPLICATIONS 
This application is a Divisional of US. application Ser. No. 
12/219,190, ?led on Jul. 17, 2008 noW abandoned, Which is a 
Divisional ofU.S. application Ser. No. 11/027,675, ?led Jan. 
3, 2005 noW abandoned, Which claims priority to US. Pro 
visional Application Ser. No. 60/533,213, ?led Dec. 31, 2003, 
Which is incorporated herein in its entirety. 
BACKGROUND OF THE INVENTION 
Considerable effort has focused on the development of 
neuronal nicotinic receptor (nAChR) agonists as therapeutic 
agents. HoWever, relatively feW studies have focused on the 
therapeutic development of nAChR antagonists. As a result, 
only a feW subtype-selective antagonists are currently avail 
able for use as pharmacological tools to investigate the physi 
ological roles of speci?c nAChR subtypes. 
It has been found that nicotine stimulates all knoWn nAChR 
subtypes, and that N-quatemiZation of nicotine converts it 
from an agonist into an antagonist With enhanced nAChR 
subtype selectivity. Several classical nAChR antagonists are 
bis-quaternary ammonium structures. Hexamethonium chlo 
ride and decamethonium bromide, both bis-quaternary 
ammonium salts, are considered simpli?ed analogs of d-tub 
ocurarine. The latter drugs have been used to distinguish 
betWeen peripheral nAChR subtypes, speci?cally neuromus 
cular and ganglionic nAChRs. More recently, quaternary 
ammonium N-n-alkyl analogs of nicotine have been reported 
to be nAChR subtype-selective antagonists. HoWever, it is 
generally believed that quaternary ammonium compounds do 
not easily access the brain due to their charge and polarity. 
Thus, there remains a need for compounds that are bioavail 
able in the brain and effective in treatment of nicotine addic 
tion and dopamine mediated disease states. 
BRIEF SUMMARY OF THE INVENTION 
The present invention is directed to the development and 
therapeutic use of nAChR subtype-selective and brain-bio 
available antagonists. The compounds are made via modi? 
cation of the nicotine molecule by (1) quaterniZation of the 
pyridine-N atom With a lipophillic substituent to afford 
N-substituted analogs, and (2) modifying the structure of the 
nicotinium cationic head group. The compounds of the inven 
tion are nicotine antagonists having the formula 
Wherein: 
R2, R3, R4, R5, R6 are each independently selected from 
hydrogen; alkyl; substituted alkyl; cycloalkyl; substituted 
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cycloalkyl, pyrrolidine; N-alkyl pyrrolidine, Where the alkyl 
chain is methyl, ethyl or propyl; unsaturated pyrrolidine; 
unsaturated N-alkyl pyrrolidine, Where the alkyl chain is 
methyl, ethyl or propyl; aZiridine; N-methyl aZiridine; aZeti 
dine; N-methyl aZetidine; unsaturated aZetidine; unsaturated 
N-methyl aZetidine; piperidine; N-methyl piperidine; unsat 
urated piperidine; unsaturated N-methyl piperidine; aZepane; 
N-methyl aZepane; unsaturated aZepane; unsaturated N-me 
thyl aZepane; aZocane; N-methyl aZocane; unsaturated aZo 
cane; unsaturated N-methyl aZocane; 1-aZa-bicyclo[3.2.1] 
octane; 1-aZa-bicyclo [2 .2. 1]heptane; 8-methyl-8-aZa 
bicyclo[3.2.1]octane; 1-aZa-tricyclo[3.3.1.1]decane; methyl 
cycloalkyl; methyl substituted cycloalkyl, methylpyrrolidine; 
methyl N-alkyl pyrrolidine, Where the alkyl chain is methyl, 
ethyl or propyl; methyl unsaturated pyrrolidine; methyl 
unsaturated N-alkyl pyrrolidine, Where the alkyl chain is 
methyl, ethyl or propyl; methyl aZiridine; methyl N-methyl 
aZiridine; methyl aZetidine; methyl N-methyl aZetidine; 
methyl unsaturated aZetidine; methyl unsaturated N-methyl 
aZetidine; methyl piperidine; methyl N-methyl piperidine; 
methyl unsaturated piperidine; methyl unsaturated N-methyl 
piperidine; methyl aZepane; methyl N-methyl aZepane; 
methyl unsaturated aZepane; methyl unsaturated N-methyl 
aZepane; methyl aZocane; methyl N-methyl aZocane; methyl 
unsaturated aZocane; methyl unsaturated N-methyl aZocane; 
methyl 1-aZa-bicyclo[3.2.1]octane; methyl 1-aZa-bicyclo 
[2 .2. 1]heptane; 8-methyl-8-aZa-bicyclo[3 .2 . 1 ]octane; 
methyl 1-aZa-tricyclo[3.3 .1 .1]decane; 
R1 is selected from alkyl, substituted alkyl, cycloalkyl, 
substituted cycloalkyl, alkenyl, substituted alkenyl, alkynyl, 
substituted alkynyl, aryl, substituted aryl, arylalkyl, substi 
tuted arylalkyl, arylalkenyl, substituted arylalkenyl, arylalky 
nyl, substituted arylalkynyl, heterocyclic, substituted hetero 
cyclic, alkoxy, alkylamine, thioalkyl; and 
X is selected from Cl, Br, I, HSO4, 1/2SO2, CH3SO3, p-TsO, 
CF3SO3 and any ion that completes the salt form of the nico 
tine antagonist; and enantomers, diastereomers and racemic 
mixes thereof. 
The nicotine antagonists of the invention are useful for the 
treatment of dopamine related conditions and dopamine-me 
diated disease states such as myasthenia gravis, Parkinson’s 
disease, AlZheimer’s disease, schizophrenia, eating disor 
ders, and drug addiction. These compounds are also useful 
When used as substitutes for psycho-stimulant self-adminis 
tration. The nicotine antagonists of the invention are particu 
larly useful for treating drug addiction due to nicotinic ago 
nists, cocaine, amphetamines, caffeine, phencyclidine, 
opiates, barbituates, benZodiaZepines, cannabinoids, halluci 
nogens and alcohol. 
The invention further includes a method of treating nico 
tine addiction by administering a formulation containing one 
or more compounds of the invention to the patient. The com 
pounds and compositions of the invention may be adminis 
tered by applying the formulation to a medical patch Which is 
then attached or adhered to the skin of the patient; providing 
an oral formulation Which is taken orally; providing a formu 
lation Which is injected into the patient With a syringe or 
similar device; providing a formulation Which is applied to 
the nasal cavity; providing a formulation Which is applied to 
the rectum; providing a formulation Which is inhaled; provid 
ing a formulation Which is applied sublingual; and any other 
means of applying the formulation to the patient. 
In another aspect of the invention the nicotine antagonists 
of the invention are administered to a patient in order to 
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inhibit dopamine release from presynaptic terminals in neu 
ronal dopamine tissue in a stereoselective and receptor-me 
diated manner. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 shows the general chemical structure of the bis-alkyl 
pyridino compounds of the invention. The identities of R and 
X groups are described herein. 
FIG. 2 shoWs the structures of ?ve series of bis-aZaaro 
matic analogs differentiated by their head groups. The abbre 
viated nomenclature is given in parentheses. 
FIG. 3 shoWs the chemical structures of N-n-alkylnico 
tinium (1-3), N-n-alkylpyridinium (4-7), and conforrnation 
ally restricted N-n-alkylnicotinium (8-17) iodides and bro 
mides. 
FIG. 4 shoWs the chemical structures of N,N'-dode 
canediyl-bis-nicotinium dibromide (18, bNDDB) and N,N' 
dodecanediyl-bis-pyridinium dibromide (19, bPDDB). 
FIG. 5 shoWs the chemical structures of the analogs of 
N-n-alkylpicolinium (on the left) and N,N'-alkyl-bis-pi 
colinium (on the right). 
DETAILED DESCRIPTION OF THE INVENTION 
During the development of nAChR receptor antagonists, 
We discovered that structural modi?cation of the nicotine 
molecule converted nicotine into a series of N-n-alkylnico 
tinium analogs exhibiting antagonist activity at speci?c 
nAChR subtypes, and several of these antagonists shoWed 
both high a?inity and subtype-selectivity (Table 4). N-n 
Alkylation of nicotine converts nicotine from an agonist into 
an antagonist at neuronal nicotinic acetylcholine receptor 
subtypes mediating nicotine-evoked dopamine release. Con 
formationally restricted analogs exhibit both high a?inity and 
selectivity at this site, and are able to access the brain due to 
their ability to act as substrates for the blood-brain barrier 
choline transporter. 
Furthermore, When the pyridine-N atom of nicotine is 
n-alkylated With chain lengths 2C6, no intrinsic activity at 
native nAChRs in dopamine release and 86Rb+ ef?ux assays is 
ob served. Moreover, nicotine-evoked dopamine release from 
striatal slices and nicotine-evoked 86Rb+ ef?ux from thalamic 
synaptosomes (a functional assay for the (x4[32* receptor) is 
inhibited by these analogs. 
The compounds of the present invention are bis-alkyl pyri 
dino compounds corresponding to the chemical structure 
shoWn in FIG. 1 (Formula I), Wherein: 
R2, R3, R4, R5, R6 are each independently selected from 
hydrogen; alkyl; substituted alkyl; cycloalkyl; substituted 
cycloalkyl, pyrrolidine; N-alkyl pyrrolidine, Where the alkyl 
chain is methyl, ethyl or propyl; unsaturated pyrrolidine; 
unsaturated N-alkyl pyrrolidine, Where the alkyl chain is 
methyl, ethyl or propyl; aZiridine; N-methyl aZiridine; aZeti 
dine; N-methyl aZetidine; unsaturated aZetidine; unsaturated 
N-methyl aZetidine; piperidine; N-methyl piperidine; unsat 
urated piperidine; unsaturated N-methyl piperidine; aZepane; 
N-methyl aZepane; unsaturated aZepane; unsaturated N-me 
thyl aZepane; aZocane; N-methyl aZocane; unsaturated aZo 
cane; unsaturated N-methyl aZocane; 1-aZa-bicyclo[3.2.1] 
octane; 1-aZa-bicyclo[2.2.1]heptane; 8-methyl-8-aZa 
bicyclo [3 .2.1]octane; 1-aZa-tricyclo [3 .3 .1 . 13’7]decane; 
methyl cycloalkyl; methyl substituted cycloalkyl, methylpyr 
rolidine; methyl N-alkyl pyrrolidine, Where the alkyl chain is 
methyl, ethyl or propyl; methyl unsaturated pyrrolidine; 
methyl unsaturated N-alkyl pyrrolidine, Where the alkyl chain 
is methyl, ethyl or propyl; methyl aZiridine; methyl N-methyl 
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aZiridine; methyl aZetidine; methyl N-methyl aZetidine; 
methyl unsaturated aZetidine; methyl unsaturated N-methyl 
aZetidine; methyl piperidine; methyl N-methyl piperidine; 
methyl unsaturated piperidine; methyl unsaturated N-methyl 
piperidine; methyl aZepane; methyl N-methyl aZepane; 
methyl unsaturated aZepane; methyl unsaturated N-methyl 
aZepane; methyl aZocane; methyl N-methyl aZocane; methyl 
unsaturated aZocane; methyl unsaturated N-methyl aZocane; 
methyl 1-aZa-bicyclo[3.2.1]octane; methyl 1-aZa-bicyclo 
[2 .2. 1]heptane; 8-methyl-8-aZa-bicyclo[3 .2 . 1 ]octane; 
methyl 1-aZa-tricyclo[3.3 .1 .13’7]decane. 
R1 is selected from but not limited to, alkyl, substituted 
alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted 
alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, 
arylalkyl, substituted arylalkyl, arylalkenyl, substituted ary 
lalkenyl, arylalkynyl, substituted arylalkynyl, heterocyclic, 
substituted heterocyclic, alkoxy, alkylamine, thioalkyl; and 
X is selected from Cl, Br, I, HSO4, 1/2SO2, CH3SO3, p-TsO 
or CF3SO3, or any other ion Which Would complete the salt 
form of the compound. 
In one embodiment of the present invention, combinations 
of R groups (i.e., R2R3, R3R4, R4R5, R5R6) represent a fused 
aromatic or unsaturated ring Z, Where Z includes, but is not 
limited to, (CH2) Where n:3-8, benZene, pyridine, pyran, 
indene, isoindene, benZofuran, isobenZofuran, benZo [b] 
thiophene, benZo[c]thiophene, indole, indolenine, isoindole, 
cyclopental[b]pyridine, pyrano[3,4-b]pyrrole, indaZole, 
indoXaZine, benZosaZole, anthranil, naphthalene, tetralin, 
decalin, chromene, coumarin, chroman-4-one, isocoumarin, 
isochromen-3-one, quinoline, isoquinoline, cinnoline, 
quinaZoline, naphthyridine, pyrido[3,4-b]-pyridine, pyridol 
[3,2-b]pyridine, pyrido[4,3,-b]-pyridine, benZoxaZine, 
anthracene, phenanthrene, phenalene, ?uorene, caraZole, 
Xanthene, acridine, octahydro-[1]pyridine, 1-methyl octahy 
dro-[1]pyridine, octahydro-indole, 1-methyl octahydro-in 
dole, octahydro-cyclopenta[b]pyrrole, lmethyl-octahydro 
cyclopenta[b]pyrrole, decahydro-quinoline, 1-methyl 
decahydro-quinoline including all possible substitution 
patterns, geometric and stereoisomers, racemic, diastereo 
meric and enantiomeric forms thereof. 
In certain compounds of the invention, ring 1 and ring 2 are 
identical or independently an unsaturated nitrogen hetero 
cycle including, but not limited to, pyrrole, pyrrolidine, pyra 
Zole, imidaZole, 1,2,3-triaZole, 1,2,4-triaZole, pyridine, 
pyridaZine, pyrimidine, pyraZine, or triaZine, including all 
possible substitution patterns, geometric and stereoisomers, 
racemic, diastereomeric and enantiomeric forms thereof. 
It is preferred that R2, R4, R5 , R6, are individually selected 
from the group consisting of hydrogen, halogen, alkyl or 
alkanoyl; R3 is individually selected from the group consist 
ing of hydrogen, halogen, alkyl, alkanoyl, amino, alkylamino, 
piperidine, N-methyl piperidine, pyrrolidine, N-methylpyr 
rolidine or quinuclidine; R1 is a branched or non-branched 
C4-C 19 alkyl; and X is iodine or bromine. 
N,N'-alkyl-bis-picolinium analogs and other bis-aZaaro 
matic analogs Were synthesiZed and assessed in nicotinic 
receptor (nAChR) assays. Preferred bis-aZaaromatic analogs 
have 6-12 carbon atoms in the alkyl chain, With an even 
number of carbon atoms in the alkyl chain being preferred to 
an odd number of carbon atoms, and a longer chain being 
preferred to a shorter chain. The most potent and subtype 
selective analog, N,N'-dodecyl-bis-picolinium bromide 
(bPiDDB), inhibited nAChRs mediating nicotine-evoked 
[3H]dopamine release (ICSOIS nM; Imax of 60%), and did not 
interact With (x4[32* or 0L7* nAChRs. Therefore, bPiDDB is 
the most preferred compound for use as a tobacco use cessa 
tion agent and for inhibiting release of dopamine. 
US 8,546,415 B2 
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The invention includes but is not limited to the use of 
compounds having the structures shoWn in FIGS. 1-5, Which 
Were prepared by quaterniZing the pyridinic nitrogen atom of 
nicotine With a lipophillic substituent group and modifying 
the structure of the nicotinium cationic head group. 
The invention also includes compositions comprising one 
or more of the chemical compounds shoWn in FIGS. 1-5 for 
use as a tobacco use cessation agent. The most preferred 
compound for this purpose is N,N'-dodecyl-bis-picolinium 
bromide (bPiDDB), shoWn in FIG. 5. 
As employed herein, the aforementioned terms are de?ned 
as folloWs: 
“loWer alkyl” refers to straight or branched chain alkyl 
radicals having in the range of about 1 up to 4 carbon atoms; 
“alkyl” refers to straight or branched chain alkyl radicals 
having in the range of about 1 up to 19 carbon atoms unless 
otherWise speci?ed, preferably 1-12 carbon atoms, and more 
preferably 6-12 carbon atoms, and most preferably 9-12 car 
bon atoms; and “substituted alkyl” refers to alkyl radicals 
further bearing one or more substituents such as hydroxy, 
alkoxy (of a loWer alkyl group), mercapto (of a loWer alkyl 
group), aryl, heterocyclic, halogen, tri?uoromethyl, cyano, 
nitro, amino, carboxyl, carbamate, sulfonyl, sulfonamide, 
and the like. 
“Cycloalkyl” refers to cyclic ring-containing radicals con 
taining in the range of about 3 up to 8 carbon atoms and 
“substituted cycloalkyl” refers to cycloalkyl radicals further 
bearing one or more substituent as set forth above; 
“alkenyl” refers to straight or branched chain hydrocarbyl 
radicals having at least one carbon-carbon double bond, and 
having in the range of about 2 up to 19 carbon atoms, prefer 
ably 2 to 12 carbon atoms, and more preferably 6 to 12 carbon 
atoms, and most preferably 9-12 carbon atoms; and “substi 
tuted alkenyl” refers to alkenyl radicals further bearing one or 
more substituents as set forth above; 
“alkynyl” refers to straight or branched chain hydrocarbyl 
radicals having at least one carbon-carbon triple bond, and 
having in the range of about 2 up to 19 carbon atoms, prefer 
ably 2 to 12 carbon atoms, and more preferably 6 to 12 carbon 
atoms, and most preferably 9-12 carbon atoms; and “substi 
tuted alkynyl” refers to alkynyl radicals further bearing one or 
more substituents as set forth above; 
“aryl” refers to aromatic radicals having in the range of 
about 6 to 24 carbon atoms and “substituted aryl” refers to 
aryl radicals further bearing one or more substituents as set 
forth above; 
“alkylaryl” refers to alkyl-substituted aryl radicals and 
“substituted alkylaryl” refers to alkylaryl radicals further 
bearing one or more substituents as set forth above; 
“arylalkyl” refers to aryl-substituted alkyl radicals and 
“substituted arylalkyl” refers to arylalkyl radicals further 
bearing one or more substituents as set forth above; 
“arylalkenyl” refers to aryl-substituted alkenyl radicals 
and “substituted arylalkenyl” refers to arylalkenyl radicals 
further bearing one or more substituents as set forth above; 
“arylalkynyl” refers to aryl-substituted alkynyl radicals 
and “substituted arylalkynyl” refers to arylalkynyl radicals 
further bearing one or more substituents as set forth above; 
“aroyl” refers to aryl-substituted species such as benZoyl 
and “substituted aroyl” refers to aroyl radicals further bearing 
one or more substituents as set forth above; 
“heterocyclic” refers to cyclic radicals containing one or 
more heteroatoms as part of the ring structure, and having in 
the range of 3 up to 24 carbon atoms and “substituted hetero 
cyclic” refers to heterocyclic radicals further bearing one or 
more substituents as set forth above; “acyl” refers to alkyl 
carbonyl species; 
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“halogen” refers to ?uoride, chloride, bromide or iodide 
radicals; and 
an “effective amount”, When used in reference to com 
pounds of the invention, refers to doses of compound su?i 
cient to provide circulating concentrations high enough to 
impart a bene?cial effect on the recipient thereof. Such levels 
typically fall in the range of about 0.001 up to 100 mg/kg/ day; 
With levels in the range of about 0.05 up to 10 mg/kg/day 
being preferred. 
The compounds of the invention exhibit various degrees of 
inhibition of dopamine release from a subset of nicotine 
receptors. In one embodiment of the invention, a nicotine 
antagonist of the invention or combination of nicotine antago 
nisits is administered to a patient in order to inhibit dopamine 
release from presynaptic terminals in neuronal dopamine tis 
sue in a stereoselective and receptor-mediated manner. The 
compounds are also able to pass through the blood-brain 
barrier by accessing the blood-brain barrier choline trans 
porter. Thus, the compounds of the invention are useful in the 
treatment of smoking addiction and other dopamine-medi 
ated conditions and diseases. Preferred compounds in the 
treatment of smoking addiction and dopamine-mediated con 
ditions and diseases include: 
N,N'-Pentane-1,5-diyl-bis-pyridinium; Diiodide (bPPel), 
N,N'-Hexane-1,6-diyl-bis-pyridinium; Diiodide (bPHxl), 
N,N'-Octane-1,8-diyl-bis-pyridinium; Diiodide (bPOl), 
N,N'-Nonane-1,9-diyl-bis-pyridinium; Dibromide (bPNB), 
N,N'-Decane-1,10-diyl-bis-pyridinium; Diiodide (bPDl), 
N,N'-Undecane-1, 1'-diyl-bis-pyridinium; Dibromide 
(bPUB), 
N,N'-Dodecane-1,12-diyl-bis-pyridinium; Dibromide (bP 
DDB), 
N,N'-Hexane-1,6-diyl-bis-picolinium; Diiodide (bPiHXl), 
N,N'-Octane-1,8-diyl-bis-picolinium; Diiodide (bPiOl), 
N,N'-Nonane-1,9-diyl-bis-picolinium; Dibromide (bPiNB), 
N,N'-Decane-1,10-diyl-bis-picolinium; Diiodide (bPiDl), 
N,N'-Undecane-1,1'-diyl-bis-picolinium; Dibromide 
(bPiUB), 
N,N'-Dodecane-1,12-diyl-bis-picolinium; Dibromide 
(bPiDDB), 
N,N'-Hexane-1,6-diyl-bis-quinolinium; Diiodide (bQHXl), 
N,N'-Octane-1,8-diyl-bis-quinolinium; Diiodide (bQOl), 
N,N'-Nonane-1,9-diyl-bis-quinolinium; Dibromide (bQNB), 
N,N'-Decane-1,10-diyl-bis-quinolinium; Diiodide (bQDl), 
N,N'-Undecane-1, 1'-diyl-bis-quinolinium; Dibromide 
(bQUB), 
N,N'-Dodecane-1,12-diyl-bis-quinolinium; Dibromide 
(bQDDB), 
N,N'-Hexane-1,6-diyl-bis-isoquinolinium; Diiodide 
(blQHxl), 
N,N'-Octane-1,8-diyl-bis-isoquinolinium; Diiodide (blQOl), 
N,N'-Nonane-1 ,9-diyl-bis-isoquinolinium; Dibromide 
(bIQNB), 
N,N'-Decane-1,10-diyl-bis-isoquinolinium; Diiodide 
(bIQDI). 
N,N'-Undecane-1, 1'-diyl-bis-isoquinolinium; Dibromide 
(bIQUB), 
N,N'-Dodecane-1,12-diyl-bis-isoquinolinium; Dibromide 
(bIQDDB), 
N,N'-Hexane-1,6-diyl-bis-nicotinium; Diiodide (bNHXl), 
N,N'-Octane-1,8-diyl-bis-nicotinium; Diiodide (bNOl), 
N,N'-Nonane-1,9-diyl-bis-nicotinium; Dibromide (bNNB), 
N,N'-Decane-1,10-diyl-bis-nicotinium; Diiodide (bNDl), 
N,N'-Undecane-1,1'-diyl-bis-nicotinium; Dibromide 
(bNUB), 
N,N'-Dodecane-1,12-diyl-bis-nicotinium; Dibromide 
(bNDDB). 
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The compounds of the invention can be prepared from 
corresponding free bases by reaction With an appropriate 
alkyl iodide using techniques knoWn to those skilled in the art 
of organic synthesis. 
The nicotine antagonists of Formula I include all possible 
diastereomers and all enantiomeric forms as Well as racemic 
mixtures. The compounds can be separated into substantially 
optically pure compounds. The compounds of the invention 
are nicotinic receptor agents, Which inhibit [3H]nicotine 
binding and [3 H] MLA binding and nicotine-evoked [3 H] DA 
release from a subset of nACh receptors that mediate nico 
tine-evoked dopamine release. Thus, the compounds of the 
invention are useful in treatment of dopamine mediated dis 
eases, such as myasthenia gravis, Parkinson’s disease, AlZhe 
imer’s disease, schizophrenia, eating disorders, and drug 
addiction. The compounds may also be used as substitutes for 
psycho-stimulant self-administration. 
The nicotine antagonists of the invention can be adminis 
tered in any useful form, such as orally, transdermally, tran 
snasally, rectally, sublinguinally, subdermally, intraocularly 
and via inhalation smokeless delivery. In general, an effective 
amount of the nicotine antagonist ranges from about). 1 to 
about 50 mg per kg of body Weight, preferably about 0.2 to 
about 35 mg per kg of body Weight. The compound or com 
bination of compounds can be administered as needed, such 
as once daily or betWeen one and three times daily, for 
example. 
The effects of the compounds of the invention on inhibition 
of nicotine-evoked dopamine release is striking, in that 
inhibitory potency is linearly related to n-alkyl chain length. 
Thus, the greater the number of carbons in the n-alkyl chain, 
the greater the potency (i.e., the loWer the IC5O value) for 
inhibition of nicotine-evoked [3 H] -dopamine over?oW. Com 
pounds bearing n-alkyl groups from C 1 to C4 are loW potency 
antagonists (IC5O>l0 uM); the most potent compound is the 
C 12 analog, NDDNI (IC5O:9 nM) (Table 1), indicating that a 
relatively long n-alkyl chain provides potent inhibition. 
Therefore, analogs With alkyl chain lengths of 6 to 12 carbon 
atoms are preferred, and analogs With alkyl chain lengths of 9 
to 12 carbon atoms are more preferred. Analogs With chain 
lengths greater than C 12 are less preferred, due to poor Water 
solubility. In the regression analysis of linearity betWeen 
n-alkyl chain length and inhibitory activity, an orderly pro 
gression in potency from C1 (NMNI) to C12 (NDDNI) is 
observed, With the exception of the n-decyl analog, NDNI, 
Which unexpectedly does not exhibit inhibitory activity at the 
nAChR subtype mediating nicotine-evoked dopamine release 
(Table l). NDNI is believed to exist in solution in a unique 
conformation that is different from the conformations of the 
other N-n-alkylnicotinium analogs. 
The most potent antagonists in this series of analogs pro 
duce 80-1 00% maximal inhibition of the response to nicotine. 
Thus, these N-n-alkylnicotinium analogs represent a neW 
class of nAChR antagonist, and the most potent compound, 
NDDNI, is at least tWo orders of magnitude more potent than 
the classical antagonist, dihydro-[3-erthyroidine (DHBE) as 
an inhibitor of nAChRs mediating nicotine-evoked dopamine 
release. In addition, kinetic studies (Schild analysis) indicate 
that the C8 compound, NONI interacts in a competitive man 
ner With these receptors. 
Unlike agonist molecules, antagonists Which are generally 
larger molecules, have been proposed to dock onto the ago 
nist-binding site, but extend beyond the region of agonist 
binding. The additional structural bulk associated With 
antagonist molecules has been proposed to prevent the recep 
tor protein from achieving the open channel form. In this 
respect, the active N-n-alkylnicotinium analogs are of signi? 
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8 
cantly larger molecular Weight than nicotine, and the steri 
cally bulky N-n-alkyl chain may interact Within a hydropho 
bic cavity extending outside the normal volume for agonist 
binding to the receptor. N-n-Alkylnicotinium analogs have 
been proposed to interact With the nAChR mediating nico 
tine-evoked dopamine release in the unprotonated form, lead 
ing to a reversal in the role of the pharmacophoric N-contain 
ing moieties. Thus, the quaternary pyridinium N-atom of the 
antagonist molecule is believed to interact With the binding 
site that normally accommodates the protonated pyrrolidine 
N-atom in the agonist binding mode, and the unprotonated 
pyrrolidine N-atom of the antagonist molecule substitutes for 
the pyridine N-atom of the agonist molecule at the hydrogen 
bonding site of the nAChR. Alternatively, these N-n-alkylni 
cotinium molecules may interact With the nicotine binding 
site in a manner alloWing free positioning of the n-alkyl chain 
into the receptor ion channel, thereby sterically inhibiting ion 
?ux through the channel. 
The N-n-alkylnicotinium analogs of the invention have 
also been evaluated for their af?nity for (x4[32* and 0L7* 
nAChRs. These compounds generally exhibit loW a?inity for 
0L7* nAChRs. In addition, these N-n-alkylnicotinium analogs 
exhibit a?inity for [3 H] -nicotine binding sites across a ~200 
fold concentration range, from ~90 nM (NDNI) to ~20 uM 
(NONI). A simple linear relationship is observed betWeen the 
length of the n-alkyl chain and a?inity for the [3H]-nicotine 
binding site, With the exception of the C8 analog, NONI. 
Thus, analogs With longer chain lengths (C9, C10 and C12) 
generally are more potent inhibitors than analogs With shorter 
chain lengths (C 1 -C7). Higher a?inity of longer n-alkyl chain 
analogs for [3 H] -nicotine binding sites may re?ect a stronger 
association With the nAChR due to an increased lipophilic 
interaction of the carbon chain With a region of the protein 
near the [3H]-nicotine binding pocket, likely rich in hydro 
phobic amino acid residues. Thus, the lipophilic interaction 
may stabiliZe the analog-receptor complex, increasing the 
inhibitory potency of longer chain analogs. 
Scatchard analyses of [3H]-nicotine saturation binding in 
the absence and presence of NONI and NDNI indicate that 
a?inity for [3H]-nicotine binding sites decreases in the pres 
ence of increasing concentrations of either NDNI or NONI, 
With no change in Bmax value, indicating that these com 
pounds interact With the high a?inity [3H]-nicotine binding 
site in a competitive manner, suggesting interaction With spe 
ci?c amino acid residues involved in [3 H] -nicotine binding or 
With nearby residues alloWing for steric hindrance of [3H] 
nicotine binding. 
The high a?inity of NONI to inhibit nicotine-evoked [3H] - 
dopamine release from superfused striatal slices and its loW 
a?inity for the [3H]-nicotine and [3H]-methyllycaconitine 
binding sites, indicate that NONI has selectivity for nAChR 
subtypes mediating nicotine-evoked dopamine release in 
striatum. The high a?inity ofNDNI combined With its lack of 
a?inity for the [3H]-methyllycaconitine binding sites and its 
lack of inhibition of nicotine-evoked [3 H] -dopamine release 
from superfused rat striatal slices, indicates that NDNI has 
selectivity for (x4[32* nAChRs. Thus, N-n-alkylnicotinium 
analogs are useful ligands for de?ning structural topogra 
phies of recognition sites of nAChR subtypes through com 
puter-assisted modeling. 
The invention Will noW be described in greater detail by 
reference to the folloWing non-limiting examples. 
Example 1 
N,N'-Pentane- l , 5-diyl-bis-pyridinium Diiodide 
(bPPeI) 
1,5-Diiodopentane (mmol) Was added to a solution (30 
mL) of dry pyridine, and the solution heated for 24 hours at 
US 8,546,415 B2 
65° C. The resulting precipitate Was ?ltered, and the product 
Washed ?ve times With dry diethyl ether. The resulting yellow 
solid Was isolated in a 90% yield. 1H NMR (300 MHZ, 
DMSO-D6) 6 9.14 (2H, d, C2&C6-H), 8.62 (1H, t, C4-H), 
8.19 (2H, t, C3&C5-H), 4.62 (2H, t, C'1-CH2), 1.92 (2H, m, 
C'2-CH2), 1.25 (1H, m, C'3-CH2). 
Example 2 
N,N'-Hexane-1,6-diyl-bis-pyridinium Diiodide 
(bPHxl) 
1,6-Diiodohexane (mmol) Was added to a solution (30 mL) 
of dry pyridine, and the solution heated for 24 hours at 650 C. 
The resulting precipitate Was ?ltered, and the product Washed 
?ve times With dry diethyl ether. The resulting yelloW solid 
Was isolated. 1H NMR (300 MHZ, DMSO-D6) 6 9.11 (2H, d, 
C2&C6-H), 8.63 (1H, t, C4-H), 8.18 (2H, t, C3&C5-H), 4.59 
(2H, t, C'1-CH2), 1.89 (2H, m, C'2-CH2), 1.28 (2H, m, C'3 
CH2). 
Example 3 
N,N'-Octane-1,8-diyl-bis-pyridinium Diiodide 
(bPOl) 
1,8-Diiodooctane (mmol) Was added to a solution (30 mL) 
of dry pyridine, and the solution heated for 24 hours at 650 C. 
The resulting precipitate Was ?ltered, and the product Washed 
?ve times With dry diethyl ether. The resulting yelloW solid 
Was isolated in a 93% yield. 1H NMR (300 MHZ, DMSO-D6) 
6 9.11 (2H, d, C2&C6-H), 8.63 (1H, t, C4-H), 8.18 (2H, t, 
C3&C5-H), 4.59 (2H, t, C'1-CH2), 1.89 (2H, m, C'2-CH2), 
1.28 (4H, m, C'3&4-CH2); 13C NMR (75 MHZ, DMSO-D6) 6 
145.3, 144.5, 127.9, 60.5, 30.6, 28.1, 25.2. 
Example 4 
N,N'-Nonane-1 ,9-diyl-bis-pyridinium Dibromide 
(bPNB) 
1,9-Dibromononane (mmol) Was added to a solution (30 
mL) of dry pyridine, and the solution heated for 24 hours at 
650 C. The resulting precipitate Was ?ltered, and the product 
Washed ?ve times With dry diethyl ether. The resulting clear 
liquid Was isolated in a 87% yield. 1H NMR (300 MHZ, 
DMSO-D6) 6 9.17 (2H, d, C2&C6-H), 8.61 (1H, t, C4-H), 
8.18 (2H, t, C3&C5-H), 4.63 (2H, t, C'1-CH2), 1.89 (2H, m, 
C'2-CH2), 1.22 (5H, m, C'3-5-CH2); 13C NMR (75 MHZ, 
DMSO-D6) 6 145.3, 144.5, 127.9, 60.5, 30.7, 28.4, 28.2, 
25.3. 
Example 5 
N,N'-Decane-1,10-diyl-bis-pyridinium Diiodide 
(bPDl) 
1,10-Diiododecane (mmol) Was added to a solution (30 
mL) of dry pyridine, and the solution heated for 24 hours at 
650 C. The resulting precipitate Was ?ltered, and the product 
Washed ?ve times With dry diethyl ether. The resulting yelloW 
solid Was isolated in a 90% yield. 1H NMR (300 MHZ, 
DMSO-D6) 6 9.10 (2H, d, C2&C6-H), 8.63 (1H, t, C4-H), 
8.19 (2H, t, C3&C5-H), 4.60 (2H, t, C'1-CH2), 1.89 (2H, m, 
C'2-CH2), 1.24 (6H, m, C'3-5-CH2); 13C NMR (75 MHZ, 
DMSO-D6) 6 145.3, 144.5, 127.9, 60.6, 30.6, 28.8, 28.1, 
25.2. 
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Example 6 
N,N'-Undecane-1 ,1'-diyl-bis-pyridinium Dibromide 
(bPUB) 
1,11-Dibromoundecane (mmol) Was added to a solution 
(30 mL) of dry pyridine, and the solution heated for 24 hours 
at 650 C. The resulting precipitate Was ?ltered, and the prod 
uct Washed ?ve times With dry diethyl ether. The resulting tan 
liquid Was isolated in a 91% yield. 1H NMR (300 MHZ, 
DMSO-D6) 6 9.18 (2H, d, C2&C6-H), 8.62 (1H, t, C4-H), 
8.19 (2H, t, C3&C5-H), 4.63 (2H, t, C'1-CH2), 1.88 (2H, m, 
C'2-CH2), 1.22 (7H, m, C'3-6-CH2). 
Example 7 
N,N'-Dodecane-1 ,12-diyl-bis-pyridinium Dibromide 
(bPDDB) 
1,12-Dibromododecane (mmol) Was added to a solution 
(30 mL) of dry pyridine, and the solution heated for 24 hours 
at 650 C. The resulting precipitate Was ?ltered, and the prod 
uct Washed ?ve times With dry diethyl ether. The resulting 
White solid Was isolated in a 93% yield. 1H NMR (300 MHZ, 
DMSO-D6) 6 9.15 (2H, d, C2&C6-H), 8.62 (1H, t, C4-H), 
8.19 (2H, t, C3&C5-H), 4.61 (2H, t, C'1-CH2), 1.88 (2H, m, 
C'2-CH2), 1.22 (8H, m, C'3-6-CH2); 13C NMR (75 MHZ, 
DMSO-D6) 6 145.3, 144.6, 127.9, 60.7, 30.8, 28.9, 28.8, 
28.5, 25.4. 
Example 8 
N,N'-Hexane-1,6-diyl-bis-quinolinium Diiodide 
(bQHxl) 
1,6-Diiodohexane (mmol) Was added to a solution (30 mL) 
of dry quinoline, and the solution heated for 24 hours at 650 C. 
The resulting precipitate Was ?ltered, and the product Washed 
?ve times With dry diethyl ether. The resulting yelloW solid 
Was isolated. 1H NMR (300 MHZ, DMSO-D6) 6 9.53 (1H, d, 
C2-H), 9.29 (1H, d, C3-H), 8.61 (1H, d, C8-H), 8.50 (1H, d, 
C4-H), 8.29 (1H, t, C7-H), 8.18 (1H, t, C5-H), 8.07 (1H, d, 
C6-H), 5.09 (2H, t, C'1-CH2), 1.96 (2H, m, C'2-CH2), 1.25 
(2H, m, C'3-CH2). 
Example 9 
N,N'-Octane-1,8-diyl-bis-quinolinium Diiodide 
(bQOI) 
1,8-Diiodooctane (mmol) Was added to a solution (30 mL) 
of dry quinoline, and the solution heated for 24 hours at 650 C. 
The resulting precipitate Was ?ltered, and the product Washed 
?ve times With dry diethyl ether. The resulting yelloW solid 
Was isolated in an 89% yield. 1H NMR (300 MHZ, DMSO 
D6) 6 9.53 (1H, d, C2-H), 9.29 (1H, d, C3-H), 8.61 (1H, d, 
C8-H), 8.50 (1H, d, C4-H), 8.29 (1H, t, C7-H), 8.18 (1H, t, 
C5-H), 8.07 (1H, d, C6-H), 5.09 (2H, t, C'1-CH2), 1.96 (2H, 
m, C'2-CH2), 1.25 (4H, m, C'3&4-CH2); 13C NMR (75 MHZ, 
DMSO-D6)6149.5,147.4,137.4,135.6,130.7,129.9,129.7, 
122.1, 118.9, 57.3, 29.5, 28.5, 25.7. 
Example 10 
N,N'-Nonane-1,9-diyl-bis-quinolinium Dibromide 
(bQNB) 
1,9-Dibromononane (mmol) Was added to a solution (30 
mL) of dry quinoline, and the solution heated for 24 hours at 
US 8,546,415 B2 
11 
65° C. The resulting precipitate Was ?ltered, and the product 
Washed ?ve times With dry diethyl ether. The resulting purple 
solid Was isolated in a 92% yield. 1H NMR (300 MHZ, 
DMSO-D6) 6 9.68 (1H, d, C2-H), 9.34 (1H, d, C3-H), 8.67 
(1H, d, C8-H), 8.55 (1H, d, C4-H), 8.27 (2H, m, C5&C7-H), 
8.07 (1H, d, C6-H), 5.09 (2H, t, C'1-CH2), 1.95 (2H, m, 
C'2-CH2), 1.19-1.45 (5H, m, C'3-5-CH2). 
Example 11 
N,N'-Decane-1,10-diyl-bis-quinolinium Diiodide 
(bQDI) 
1,10-Diiododecane (mmol) Was added to a solution (30 
mL) of dry quinoline, and the solution heated for 24 hours at 
650 C. The resulting precipitate Was ?ltered, and the product 
Washed ?ve times With dry diethyl ether. The resulting yelloW 
solid Was isolated in a 91% yield. 1H NMR (300 MHZ, 
DMSO-D6) 6 9.53 (1H, d, C2-H), 9.29 (1H, d, C3-H), 8.61 
(1H, d, C8-H), 8.50 (1H, d, C4-H), 8.29 (1H, t, C7-H), 8.18 
(1H, t, C5-H), 8.06 (1H, d, C6-H), 5.04 (2H, t, C'1-CH2), 1.96 
(2H, m, C'2-CH2), 1.32 (6H, m, C'3-5-CH2); 13C NMR (75 
MHZ,DMSO-D6)6149.5,147.4,137.4,135.6,130.7,129.9, 
129.7, 122.1, 118.9, 57.3, 29.5, 28.9, 28.5, 25.7. 
Example 12 
N,N'-Undecane-1,1'-diyl-bis-quinolinium Dibromide 
(bQUB) 
1,11-Dibromoundecane (mmol) Was added to a solution 
(30 mL) of dry quinoline, and the solution heated for 24 hours 
at 650 C. The resulting precipitate Was ?ltered, and the prod 
uct Washed ?ve times With dry diethyl ether. The resulting 
purple solid Was isolated in a 87% yield. 1H NMR (300 MHZ, 
CDCl3) 6 9.54 (1H, d, C2-H), 9.28 (1H, d, C3-H), 8.60 (1H, 
d, C8-H), 8.48 (1H, d, C4-H), 8.27 (1H, t, C7-H), 8.16 (1H, t, 
C5-H), 8.05 (1H, d, C6-H), 5.03 (2H, t, C'1-CH2), 1.95 (2H, 
m, C'2-CH2), 1.15-1.48 (7H, m, C'3-6-CH2); 13C NMR (75 
MHZ, DMSO-d6) 6 149.5, 147.4, 137.4, 135.6, 130.7, 129.9, 
129.7, 122.1, 118.9, 57.3, 29.5, 28.9, 28.8, 28.5, 25.7. 
Example 13 
N,N'-Dodecane-1,12-diyl-bis-quinolinium 
Dibromide (bQDDB) 
1,12-Dibromododecane (mmol) Was added to a solution 
(30 mL) of dry quinoline, and the solution heated for 24 hours 
at 650 C. The resulting precipitate Was ?ltered, and the prod 
uct Washed ?ve times With dry diethyl ether. The resulting 
yelloW solid Was isolated in a 92% yield. 1H NMR (300 MHZ, 
DMSO-D6) 6 9.58 (1H, d, C2-H), 9.29 (1H, d, C3-H), 8.61 
(1H, d, C8-H), 8.50 (1H, d, C4-H), 8.29 (1H, t, C7-H), 8.18 
(1H, t, C5-H), 8.04 (1H, d, C6-H), 5.04 (2H, t, C'1-CH2), 1.95 
(2H, m, C'2-CH2), 1.2-1 .4 (8H, m, C'3-6-CH2); l3CNMR (75 
MHZ,DMSO-D6)6149.5,147.4,137.4,135.6,130.7,129.9, 
129.7, 122.1, 118.9, 57.3, 29.5, 28.9, 28.8, 28.5, 25.7. 
Example 14 
N,N'-Hexane-1,6-diyl-bis-picolinium Diiodide 
(bPiOl) 
1,6-Diiodohexane (mmol) Was added to a solution (30 mL) 
of 3-picoline, and the solution heated for 24 hours at 650 C. 
The resulting precipitate Was ?ltered, and the product Washed 
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?ve times With dry diethyl ether. The precipitate Was then 
dissolved in Water (30 mL) and extracted With chloroform 
(3><30 mL). The aqueous layer Was collected and evaporated 
to dryness on a rotary evaporator. The resulting pale yelloW 
solid Was isolated. 1H NMR (300 MHZ, DMSO-D6) 6 9.03 
(1H, s, C2-H), 8.93 (1H, d, C6-H), 8.46 (1H, d, C4-H), 8.08 
(1H, t, C5-H), 4.55 (2H, t, C'1-CH2), 2.74 (3H, s, C3-CH3), 
2.13 (2H, m, C'2-CH2), 1.46 (2H, m, C'3-CH2). 
Example 15 
N,N'-Octane-1,8-diyl-bis-picolinium Diiodide 
(bPiOl) 
1,8-Diiodooctane (mmol) Was added to a solution (30 mL) 
of 3-picoline, and the solution heated for 24 hours at 650 C. 
The resulting precipitate Was ?ltered, and the product Washed 
?ve times With dry diethyl ether. The precipitate Was then 
dissolved in Water (30 mL) and extracted With chloroform 
(3><30 mL). The aqueous layer Was collected and evaporated 
to dryness on a rotary evaporator. The resulting pale yelloW 
solid Was isolated in a 94% yield. 1H NMR (300 MHZ, 
DMSO-D6) 6 9.18 (1H, s, C2-H), 8.96 (1H, d, C6-H), 8.46 
(1H, d, C4-H), 8.07 (1H, t, C5-H), 4.62 (2H, t, C'1-CH2), 2.50 
(3H, s, C3-CH3), 1.94 (2H, m, C'2-CH2), 1.27 (4H, m, C'3&4 
CH2);13C NMR (75 MHZ, DMSO-D6) 6 145.5, 143.9, 141.7, 
138.5, 127.1, 60.4, 30.5, 28.1, 25.2, 17.9. 
Example 16 
N,N'-Nonane-1,9-diyl-bis-picolinium Dibromide 
(bPiNB) 
1,9-Dibromononane (mmol) Was added to a solution (30 
mL) of 3-picoline, and the solution heated for 24 hours at 650 
C. The resulting precipitate Was ?ltered, and the product 
Washed ?ve times With dry diethyl ether. The precipitate Was 
then dissolved in Water (30 mL) and extracted With chloro 
form (3 x30 mL). The aqueous layer Was collected and evapo 
rated to dryness on a rotary evaporator. The resulting tan 
liquid Was isolated in a 90% yield. 1H NMR (300 MHZ, 
DMSO-D6) 6 9.17 (1H, s, C2-H), 9.04 (1H, d, C6-H), 8.47 
(1H, d, C4-H), 8.08 (1H, t, C5-H), 4.60 (2H, t, C'1-CH2), 2.50 
(3H, s, C3-CH3), 1.92 (2H, m, C'2-CH2), 1.27 (5H, m, C'3 
5-CH2); 13C NMR (75 MHZ, DMSO-D6) 6 145.5, 144.1, 
141.8, 138.5, 127.1, 60.4, 30.7, 28.5, 28.3, 25.4, 17.9. 
Example 17 
N,N'-Decane-1,10-diyl-bis-picolinium Diiodide 
(bPiDl) 
1,10-Diiododecane (mmol) Was added to a solution (30 
mL) of 3-picoline, and the solution heated for 24 hours at 650 
C. The resulting precipitate Was ?ltered, and the product 
Washed ?ve times With dry diethyl ether. The precipitate Was 
then dissolved in Water (30 mL) and extracted With chloro 
form (3 x30 mL). The aqueous layer Was collected and evapo 
rated to dryness on a rotary evaporator. The resulting off White 
solid Was isolated in a 92% yield. 1H NMR (300 MHZ, 
CDCl3) 6 9.04 (1H, s, C2-H), 8.94 (1H, d, C6-H), 8.46 (1H, d, 
C4-H), 8.06 (1H, t, C5-H), 4.58 (2H, t, C'1-CH2), 2.50 (3H, s, 
C3-CH3), 1.90 (2H, m, C'2-CH2), 1.27 (6H, m, C'3-5-CH2). 
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Example 18 
N,N'-Undecane-1 ,1'-diyl-bis-picolinium Dibromide 
(bPiUB) 
1,11-Dibromoundecane (mmol) Was added to a solution 
(30 mL) of 3-picoline, and the solution heated for 24 hours at 
65° C. The resulting precipitate Was ?ltered, and the product 
Washed ?ve times With dry diethyl ether. The precipitate Was 
then dissolved in Water (30 mL) and extracted With chloro 
form (3 x30 mL). The aqueous layer Was collected and evapo 
rated to dryness on a rotary evaporator. The resulting tan 
liquid Was isolated in a 90% yield. 1H NMR (300 MHZ, 
DMSO-D6) 6 9.10 (1H, s, C2-H), 8.98 (1H, d, C6-H), 8.46 
(1H, d, C4-H), 8.07 (1H, t, C5-H), 4.58 (2H, t, C'1-CH2), 2.50 
(3H, s, C3-CH3), 1.90 (2H, m, C'2-CH2), 1.26 (7H, m, C'3 
6-CH2); 13C NMR (75 MHZ, DMSO-D6) 6 145.5, 144.0, 
141.8, 138.5, 127.1, 60.5, 30.7, 28.8, 28.7, 28.4, 25.4, 17.9. 
Example 19 
N,N'-Dodecane-1,12-diyl-bis-picolinium Dibromide 
(bPiDDB) 
1,12-Dibromododecane (mmol) Was added to a solution 
(30 mL) of 3-picoline, and the solution heated for 24 hours at 
650 C. The resulting precipitate Was ?ltered, and the product 
Washed ?ve times With dry diethyl ether. The precipitate Was 
then dissolved in Water (30 mL) and extracted With chloro 
form (3 x30 mL). The aqueous layer Was collected and evapo 
rated to dryness on a rotary evaporator. The resulting tan 
liquid Was isolated in a 92% yield. 1H NMR (300 MHZ, 
CDCl3) 6 9.04 (1H, s, C2-H), 8.94 (1H, d, C6-H), 8.46 (1H, d, 
C4-H), 8.16 (1H, t, C5-H), 4.55 (2H, t, C'1-CH2), 2.50 (3H, s, 
C3-CH3), 1.90 (2H, m, C'2-CH2), 1.25 (8H, m, C'3-6-CH2). 
Example 20 
N,N'-Hexane-1,6-diyl-bis-nicotinium Diiodide 
(bNHxl) 
S-(—)-Nicotine (30.8 mmol) Was dissolved in glacial acetic 
acid (35 mL) and the solution Was stirred at ambient tempera 
ture for 5 minutes. 1,6-Diiodohexane (15.4 mmol) Was added 
to the solution and the mixture stirred and re?uxed for 3 days. 
The mixture Was then evaporated under reduced pressure to 
remove the solvent and the resulting oil Was treated With an 
aqueous mixture of sodium bicarbonate. The aqueous mix 
ture Was extracted With ethyl ether (3 x50 mL) and chloroform 
(3><50 mL) and the aqueous layer collected and Was evapo 
rated to dryness on a rotary evaporator, and the resulting solid 
Was treated With chloroform and ?ltered. The ?ltrate Was 
collected and evaporated to dryness. The resulting yelloW oil 
Was isolated. 1H NMR (300 MHZ, CDCl3), 6 9.44 (1H, s, 
C2-H), 9.38 (1H, d, C6-H), 8.44 (1H, d, C4-H), 8.13 (1H, m. 
C3-H), 4.95 (2H, t, C"1-CH2), 4.03 (1H, t, pyrrolidine CH2), 
3.25 (1H, t, pyrrolidine CH2), 2.49 (2H, m, C"2-CH2), 2.23 
(3H, s, pyrrolidine N4CH3), 1.60-2.19 (5H, m, pyrrolidine 
CH2CH2), 1.30-1.55 (2H, m, C"3-CH2). 
Example 21 
N,N'-Octane-1,8-diyl-bis-nicotinium Diiodide 
(bNOl) 
S-(—)-Nicotine (30.8 mmol) Was dissolved in glacial acetic 
acid (35 mL) and the solution Was stirred at ambient tempera 
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ture for 5 minutes. 1,8-Diiodooctane (15.4 mmol) Was added 
to the solution and the mixture stirred and re?uxed for 3 days. 
The mixture Was then evaporated under reduced pressure to 
remove the solvent and the resulting oil Was treated With an 
aqueous mixture of sodium bicarbonate. The aqueous mix 
ture Was extracted With ethyl ether (3 x50 mL) and chloroform 
(3x50 mL) and the aqueous layer collected and Was evapo 
rated to dryness on a rotary evaporator, and the resulting solid 
Was treated With chloroform and ?ltered. The ?ltrate Was 
collected and evaporated to dryness. The resulting yelloW oil 
Was isolated in a 15% yield. 1H NMR (300 MHZ, CDCl3), 6 
9.58 (1H, s, C2-H), 9.50 (1H, d, C6-H), 8.47 (1H, d, C4-H), 
8.03 (1H, m. C3-H), 4.96 (2H, t, C"1-CH2), 3.65 (1H, t, 
pyrrolidine CH2), 3.24 (1H, t, pyrrolidine CH2), 2.49 (2H, m, 
C"2-CH2), 2.25 (3H, s, pyrrolidine N%H3), 1.60-2.19 (5H, 
m, pyrrolidine CH2CH2), 1.40-1.60 (4H, m, C"3&4-CH2); 
13C NMR (75 MHZ, CDCl3) 6 146.9, 143.8, 143.6, 143.5, 
128.3, 66.8, 61.7, 57.0, 40.8, 36.1, 32.0, 27.7, 25.2, 23.5. 
Example 22 
N,N'-Nonane- 1 ,9-diyl-bis-nicotinium Dibromide 
(bNNB) 
S-(—)-Nicotine (30.8 mmol) Was dissolved in glacial acetic 
acid (35 mL) and the solution Was stirred at ambient tempera 
ture for 5 minutes. 1,9-Dibromononane (15.4 mmol) Was 
added to the solution and the mixture stirred and re?uxed for 
3 days. The mixture Was then evaporated under reduced pres 
sure to remove the solvent and the resulting oil Was treated 
With an aqueous mixture of sodium bicarbonate. The aqueous 
mixture Was extracted With ethyl ether (3x50 mL) and chlo 
roform (3x50 mL) and the aqueous layer collected and Was 
evaporated to dryness on a rotary evaporator, and the resulting 
solid Was treated With chloroform and ?ltered. The ?ltrate 
Was collected and evaporated to dryness. The resulting yelloW 
oil Was isolated in a % yield. 1H NMR (300 MHZ, CDCl3), 6 
9.75 (1H, s, C2-H), 9.56 (1H, d, C6-H), 8.49 (1H, d, C4-H), 
8.08 (1H, m. C3-H), 5.05 (2H, t, C"1-CH2), 3.65 (1H, t, 
pyrrolidine CH2), 3.25 (1H, t, pyrrolidine CH2), 2.48 (2H, m, 
C"2-CH2), 2.25 (3H, s, pyrrolidine N%H3), 1.60-2.23 (5H, 
m, pyrrolidine CH2CH2), 1.30-1.60 (5H, m, C"3-5-CH2). 
Example 22 
N,N'-Decane-1,10-diyl-bis-nicotinium Diiodide 
(bNDl) 
S-(—)-Nicotine (30.8 mmol) Was dissolved in glacial acetic 
acid (35 mL) and the solution Was stirred at ambient tempera 
ture for 5 minutes. 1,10-Diiododecane (15.4 mmol) Was 
added to the solution and the mixture stirred and re?uxed for 
3 days. The mixture Was then evaporated under reduced pres 
sure to remove the solvent and the resulting oil Was treated 
With an aqueous mixture of sodium bicarbonate. The aqueous 
mixture Was extracted With ethyl ether (3x50 mL) and chlo 
roform (3x50 mL) and the aqueous layer collected and Was 
evaporated to dryness on a rotary evaporator, and the resulting 
solid Was treated With chloroform and ?ltered. The ?ltrate 
Was collected and evaporated to dryness. The resulting yelloW 
oil Was isolated in a 27% yield. 1H NMR (300 MHZ, CDCl3) 
6 9.55 (1H, s, C2-H), 9.44 (1H, d, C6-H), 8.53 (1H, d, C4-H), 
8.09 (1H, m. C3-H), 4.98 (2H, t, C"1-CH2), 3.74 (1H, t, 
pyrrolidine CH2), 3.30 (1H, t, pyrrolidine CH2, 2.50 (2H, m, 
C"2-CH2), 2.29 (3H, s, pyrrolidine N%H3), 1.65-2.20 (5H, 
m, pyrrolidine CH2CH2), 1.30-1.57 (6H, m, C"3-5-CH2); l3C 
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NMR (75 MHZ, CDC13) 6 146.6, 143.9><2, 143.4, 128.4, 66.9, 
61.9, 57.0, 40.8, 36.1, 32.1, 28.5, 28.2, 25.8, 23.5. 
Example 23 
N,N'-Undecane-1 ,1'-diyl-bis-nicotinium Dibromide 
(bNUB) 
S-(—)-Nicotine (30.8 mmol) Was dissolved in glacial acetic 
acid (35 mL) and the solution Was stirred at ambient tempera 
ture for 5 minutes. 1,11-Dibromoundecane (15.4 mmol) Was 
added to the solution and the mixture stirred and re?uxed for 
3 days. The mixture Was then evaporated under reduced pres 
sure to remove the solvent and the resulting oil Was treated 
With an aqueous mixture of sodium bicarbonate. The aqueous 
mixture Was extracted With ethyl ether (3x50 mL) and chlo 
roform (3x50 mL) and the aqueous layer collected and Was 
evaporated to dryness on a rotary evaporator, and the resulting 
solid Was treated With chloroform and ?ltered. The ?ltrate 
Was collected and evaporated to dryness. The resulting yelloW 
oil Was isolated in a % yield. 1H NMR (300 MHZ, CDCl3) 6 
9.70 (1H, s, C2-H), 9.47 (1H, d, C6-H), 8.49 (1H, d, C4-H), 
8.12 (1H, m. C3-H), 5.02 (2H, t, C"1-CH2), 3.65 (1H, t, 
pyrrolidine CH2), 3.26 (1H, t, pyrrolidine CH2), 2.49 (2H, m, 
C"2-CH2), 2.25 (3H, s, pyrrolidine N%H3), 1.60-2.20 (5H, 
m, pyrrolidine CH2CH2), 1.20-1 .50 (8H, m, C"3-6-CH2); 13C 
NMR (75 MHZ, CDCl3) 6 146.5, 144.2, 143.7, 143.5, 128.4, 
66.9, 61.9, 56.9, 40.7, 36.1, 32.2, 28.8, 28.7, 28.6, 25.9, 23.4. 
Example 24 
N,N'-Dodecane-1,12-diyl-bis-nicotinium Dibromide 
(bNDDB) 
S-(—)-Nicotine (30.8 mmol) Was dissolved in glacial acetic 
acid (35 mL) and the solution Was stirred at ambient tempera 
ture for ?ve minutes. 1,12-Dibromododecane (15.4 mmol) 
Was added to the solution and the mixture stirred and re?uxed 
for 3 days. The mixture Was then evaporated under reduced 
pressure to remove the solvent and the resulting oil Was 
treated With an aqueous mixture of sodium bicarbonate. The 
aqueous mixture Was extracted With ethyl ether (3x50 mL) 
and chloroform (3x50 mL) and the aqueous layer collected 
and Was evaporated to dryness on a rotary evaporator, and the 
resulting solid Was treated With chloroform and ?ltered. The 
?ltrate Was collected and evaporated to dryness. The resulting 
yelloW liquid Was isolated in a 35% yield. 1H NMR (300 
MHZ, CDCl3) 6 9.66 (1H, s, C2-H), 9.38 (1H, d, C6-H), 8.46 
(1H, d, C4-H), 8.10 (1H, m. C3-H), 5.01 (2H, t, C"1-CH2), 
3.61 (1H, t, pyrrolidine CH2), 3.25 (1H, t, pyrrolidine CH2), 
2.45 (2H, m, C"2-CH2), 2.23 (3H, s, pyrrolidine NiCH3), 
1.60-2.19 (5H, m, pyrrolidine CH2CH2), 1.20-1.50 (8H, m, 
C"3-6-CH2); 13C NMR (75 MHZ, CDCl3) 6 146.6, 144.2, 
143.7, 143.4, 128.5, 67.0, 62.0, 60.0, 40.8, 36.1, 32.4, 29.0, 
28.8, 28.7, 26.0, 23.5. 
Example 25 
N,N'-Hexame-1,6-diyl-bis-isoquinolinium Diiodide 
(blQHxl) 
1,6-Diiodohexane (mmol) Was added to a solution (30 mL) 
of isoquinoline, and the solution heated for 24 hours at 650 C. 
The resulting precipitate Was ?ltered, and the product Washed 
?ve times With dry diethyl ether. The resulting yelloW solid 
Was isolated. 
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Example 26 
N,N'-Octane-1,8-diyl-bis-isoquinolinium Diiodide 
(blQOl) 
1,8-Diiodooctane (mmol) Was added to a solution (30 mL) 
of isoquinoline, and the solution heated for 24 hours at 650 C. 
The resulting precipitate Was ?ltered, and the product Washed 
?ve times With dry diethyl ether. The resulting yelloW solid 
Was isolated in an 92% yield. 1H NMR (300 MHZ, DMSO 
D6) 6 10.05 (1H, d, C1-H), 8.77 (1H, d, C3-H), 8.58 (1H, d, 
C8-H), 8.48 (1H, d, C4-H), 8.35 (1H, d, C7-H), 8.26 (1H, t, 
C5-H), 8.07 (1H, t, C6-H), 4.68 (2H, t, C'1-CH2), 2.00 (2H, 
m, C'2-CH2), 1.30 (4H, m, C'3&4-CH2). 
Example 27 
N,N'-Nonane-1,9-diyl-bis-isoquinolinium Dibromide 
(blQNB) 
1,9-Dibromononane (mmol) Was added to a solution (30 
mL) of isoquinoline, and the solution heated for 24 hours at 
650 C. The resulting precipitate Was ?ltered, and the product 
Washed ?ve times With dry diethyl ether. The resulting purple 
solid Was isolated in a 92% yield. 1H NMR (300 MHZ, 
DMSO-D6) 6 10.17 (1H, d, C1-H), 8.85 (1H, d, C3-H), 8.62 
(1H, d, C8-H), 8.49 (1H, d, C4-H), 8.36 (2H, d, C7-H), 8.26 
(2H, t, C5-H), 8.08 (1H, t, C6-H), 4.72 (2H, t, C'1-CH2), 2.02 
(2H, m, C'2-CH2), 1.78 (1H, m, C'3-CH2), 1.19-1.50 (4H, m, 
C'3-5-CH2). 
Example 28 
N,N'-Decane-1,10-diyl-bis-isoquinolinium Diiodide 
(blQDl) 
1,10-Diiododecane (mmol) Was added to a solution (30 
mL) of isoquinoline, and the solution heated for 24 hours at 
650 C. The resulting precipitate Was ?ltered, and the product 
Washed ?ve times With dry diethyl ether. The resulting yelloW 
solid Was isolated in a 92% yield. 1H NMR (300 MHZ, 
DMSO-D6) 6 10.07 (1H, d, C1-H), 8.78 (1H, d, C3-H), 8.58 
(1H, d, C8-H), 8.48 (1H, d, C4-H), 8.36 (1H, d, C7-H), 8.26 
(1H, t, C5-H), 8.07 (1H, t, C6-H), 4.69 (2H, t, C'1-CH2), 2.0 
(2H, m, C'2-CH2), 1.15-1.50 (6H, m, C'3-5-CH2). 
Example 29 
N,N'-Undecane-1,1'-diyl-bis-isoquinolinium Dibro 
mide (blQUB) 
1,11-Dibromoundecane (mmol) Was added to a solution 
(30 mL) of isoquinoline, and the solution heated for 24 hours 
at 650 C. The resulting precipitate Was ?ltered, and the prod 
uct Washed ?ve times With dry diethyl ether. The resulting 
off-White solid Was isolated. 1H NMR (300 MHZ, DMSO-D6) 
6 10.07 (1H, d, C1-H), 8.78 (1H, d, C3-H), 8.57 (1H, d, 
C8-H), 8.48 (1H, d, C4-H), 8.35 (1H, d, C7-H), 8.25 (1H, t, 
C5-H), 8.07 (1H, t, C6-H), 4.69 (2H, t, C'1-CH2), 2.0 (2H, m, 
C'2-CH2), 1.73 (1H, m, C'3-CH2), 1.15-1.50 (6H, m, C'3-6 
CH2). 
Example 30 
N,N'-Dodecane-1,12-diyl-bis-isoquinolinium 
Dibromide (blQDDB) 
1,12-Dibromododecane (mmol) Was added to a solution 
(30 mL) of isoquinoline, and the solution heated for 24 hours 
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at 65° C. The resulting precipitate Was ?ltered, and the prod 
uct Washed ?ve times With dry diethyl ether. The resulting 
off-White solidWas isolated. 1H NMR (300 MHZ, DMSO-D6) 
6 10.06 (1H, d, C1-H), 8.78 (1H, d, C3-H), 8.58 (1H, d, 
C8-H), 8.48 (1H, d, C4-H), 8.35 (1H, d, C7-H), 8.25 (1H, t, 
C5-H), 8.07 (1H, t, C6-H), 4.70 (2H, t, C'1-CH2), 2.0 (2H, m, 
C'2-CH2), 1.75 (1H, m, C'3-CH2), 1.15-1.40 (7H, m, C'3-6 
CH2). 
Example 31 
[3H]Nicotine Binding Assay 
Striata from tWo rats Were dissected, pooled, and homog 
eniZed With a Tamar polytron in 10 volumes of ice-cold modi 
?ed Krebs-HEPES buffer (20 mM HEPES, 118 mM NaCl, 
4.8 mM KCl, 2.5 mM CaCl2, 1.2 mM MgSO4, adjusted to pH 
7.5). The homogenates Were incubated at 37° C. for ?ve 
minutes and centrifuged at 15,000 g for 20 minutes. The pellet 
Was resuspended in ten volumes of ice-cold MilliQ Water, 
incubated for ?ve minutes at 37° C., and centrifuged at 15,000 
g for 20 minutes The second pellet Was then resuspended in 
ten volumes of fresh ice-cold 10% Krebs-HEPES buffer, 
incubated at 37° C., and centrifuged at 15,000 g for 20 min 
utes. The latter sequence of resuspension, incubation, and 
centrifugation Was repeated. The pellet Was froZen under 
fresh 10% Krebs-HEPES buffer and stored at —40° C. until 
assay. Upon assay, the pellet Was resuspended in the Krebs 
HEPES buffer, incubated at 37° C. for ?ve minutes, and 
centrifuged at 15,000 g for 20 minutes. The ?nal pellet Was 
resuspended in 3 .6 ml ice-cold MilliQ Water Which provided 
for approximately 200 pg protein per 100 pl aliquot. Compe 
tition assays Were performed in duplicate in a ?nal volume of 
200 pl Krebs-HEPES buffer containing 250 mmol Tris buffer 
(pH 7.5 at 4° C.). Reactions Were initiated by addition of 100 
pl of membrane suspension to 3 mM [3H]nicotine (50 pl) and 
one of at least nine concentrations of analog (50 pl). After a 90 
minute incubation at 4° C., reactions Were terminated by 
dilution of the samples With 3 ml of ice-cold Krebs-HEPES 
buffer folloWed immediately by ?ltration through Whatman 
GF/B glass ?ber ?lters (presoaked in 0.5% polyethylene 
imine) using a Brandel Cell Harvester. Filters Were rinsed 
three times With 3 ml of ice-cold Krebs-HEPES buffer, trans 
ferred to scintillation vials, and 5 ml scintillation cocktail 
(Research Products lntemational Corp., Mt. Prospect, Ill.) 
added. Nonspeci?c binding determined in triplicate Was 
de?ned as binding in the presence of 10 pM nicotine. Binding 
parameters Were determined using the Weighted, least 
squares non-linear regression. 
The bis-alkyl pyridino analogs Were evaluated for their 
ability to displace [3H]nicotine binding from rat striatal mem 
branes. The results are summariZed in Table 1. Furthermore, 
the displacement by the analogs Was compared to that pro 
duced by NONI, NDNI, and DHBE. All of the compounds 
examined displaced [3H]nicotine binding With loWer af?ni 
ties than DHBE. HoWever, bNDl had a value approaching the 
K- of DHBE and NDNI. Additionally, the N-alkyl-bis-pyri 
dinium series demonstrated an increase in a?inity for the 
receptor as the chain length of the carbon bridge increased. 
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TABLE 1 
Speci?c Binding of [3H]—Nicotine to Rat Striatal Nicotinic 
Acetvlcholine Receptors in the Presence of bis-Alkvl Pvridino Analogs 
Compound Kl- (pM)" 
NONI 49.3 
NDNI 0.1 1 
DHBE 0.15 
bPPeI >100 
bPHxI NDZ’ 
bPOI 33 .9 
bPNB 24.1 
bPDI 18.6 
bPUB 14.4 
bPDDB 9.14 
bPiHxI ND 
bPiOI >100 
bPiNB 66.7 
bPiDI >100 
bPiUB 82.0 
bPiDDB 33 .0 
bQHxI ND 
bQOI >100 
bQNB 20.1 
bQDI >100 
bQUB 38.3 (n = 2) 
bQDDB >100 
bIQHxI ND 
bIQOI >100 
bIQNB >100 
bIQDI >100 
bIQUB ND 
bIQDDB >100 
bNHxI ND 
bNOI 1.50 
bNNB 4.31 
bNDI 0.28 
bNUB 0.37 
bNDDB 1 .43 
“Data are expressed as frnol/rng ofprotein ofat least 3 independent experiments. Speci?c 
binding is calculated as the difference between the total binding of3 nM [3H]-nicotine and 
nonspeci?c binding in the presence oflO pM cold nicotine. 
= Not Determined 
Example 32 
[3H]MLA Binding Assay 
Rat brain Was dissected into the Whole brain tissue Without 
cortex, striatum and cerebellum and Was froZen in liquid 
nitrogen and stored at —70° C. until use. 
The brain tissue Was homogenized With a Tekmar Polytron 
(setting 40) in 20 volumes of ice-cold hypotonic buffer (2 mM 
HEPES, 14.4 mM NaCl, 0.15 mM KCl, 0.2 mM CaCl2 and 
0.1 mM MgSO4, pH:7.5). The homogenate Was incubated at 
37° C. for ten minutes and centrifuged at 25,000><g for 15 
minutes at 40° C. The pellet Was Washed three times more by 
resuspension in the 20 volumes of the same buffer and cen 
trifugation at the above parameters. The ?nal pellet Was 
stored at —20° C. under 4.6 ml of the incubation buffer and 
Was suspended just before the incubation With radioligand. 
The binding of [3H]MLA to probe (x7-type neuronal nico 
tinic acetylcholine receptors Was measured using a modi?ca 
tion of the method of Davies et al., “Characterisation of the 
binding of [3H]methyllycaconitine: a neW radioligand for 
labelling (x7-type neuronal nicotinic acetylcholine receptors,’ 
Neuropharmocology, 38, 679-690 (1999). [3H]MLA (25.4 
Ci/mmol) Was purchased from Tocris Cookson Ltd., Bristol, 
UK. Binding Was performed in duplicate, in a ?nal volume of 
250 ml of the incubation medium, containing 20 mM HEPES, 
144 mM NaCl, 1.5 mM KCl, 2 mM CaCl2, 1 mM MgSO4 and 
0.05% BSA, pH:7.5. Reaction Was initiated by the addition 
of 100 pl of membrane suspension to the samples containing 
US 8,546,415 B2 
19 
a desired concentration of test compounds and 2.5 mM [3 H] 
MLA (?nal concentration) and incubated for 2 hours at room 
temperature. Total binding Was measured in the absence of 
unlabelled ligand and nonspeci?c binding Was determined in 
the presence of 1 uM unlabelled MLA. The binding reaction 
Was terminated by dilution of samples With 3 ml of ice-cold 
incubation buffer folloWed by immediate ?ltration through 
presoaked in 0.5% polyethylenimine glass ?ber ?lters (S&S, 
grade #32) using a Brandel harvester system. Filters Were 
rinsed three times With 3 ml of ice-cold buffer, transferred to 
scintillation vials and 4 ml of scintillation cocktail Was added. 
Protein Was measured using the Bradford dye-binding proce 
dure With bovine serum albumin as the standard. 
In order to determine if these compounds have selectivity 
at the (X7 receptor subtype, the bis-alkyl pyridino analogs 
Were evaluated for their ability to displace [3H]MLA binding 
from rat brain membranes, as a re?ection of their interaction 
With the (X7 receptor (Table 2). In addition, the classical (X7 
receptor antagonist ot-bungarotoxin Was also examined in this 
assay for comparison. ot-Bungarotoxin afforded a K- value of 
28.6154 nM in this assay. The results from the competition 
binding assay shoWed that N,N'-dodecane-1,12-diyl-bis-py 
ridinium; Dibromide (bPDDB) and the N-alkyl-bis-quino 
linium analogs demonstrated moderate binding a?inity in the 
[3 H] MLA assay, While the other compounds shoWed no a?in 
ity no af?nity for the (X7 subtype. 
TABLE 2 
[3HlMLA Binding in the Presence ofbis-Alkyl Pyridino Analogs 
Compound K,- (pM)" 
NONI >100 
NDNI >100 
DH[5E NDZ’ 
bPPeI >100 
bPHxI ND 
bPOI >100 
bPNB >100 
bPDI >100 
bPUB 50.2 
bPDDB 35 .6 
bPiHxI ND 
bPiOI >100 
bPiNB >100 
bPiDI >100 
bPiUB >100 
bPiDDB >100 
bQHxI ND 
bQOI 2.01 
bQNB 3 .40 
bQDI 7.32 
bQUB 2.44 
bQDDB 1 .57 
bIQHxI ND 
bIQOI 8.55 
bIQNB 13 .1 
bIQDI 5 .50 
bIQUB 24.1 
bIQDDB 12.3 
hNHxI ND 
bNOI >100 
bNNB >100 
bNDI >100 
bNUB >100 
bNDDB >100 
Tata are expressed as frnol/rng of protein of 3 independent experiments. Speci?c binding is 
calculated as the difference between the total binding of2.5 nM [3H]-MLA to the receptors 
alone and its nonspeci?c binding in the presence of 1 11M cold MLA. 
bND = Not Determined 
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Example 33 
[3H] DA Release Assay 
Rat striatal slices (500 um thickness, 6-8 mg Wet Weight) 
Were incubated for 30 minutes in Krebs buffer (118 mM 
NaCl, 4.7 mM KCl, 1.2 mM MgCl2, 1.0 mM NaH2PO4, 1.3 
mM CaCl2, 11.1 mM glucose, 25 mM NaHCO3, 0.11 mM 
L-ascorbic acid, and 0.004 mM disodium EDTA; pH 7.4, and 
saturated With 95% 02/ 5% CO2) in a metabolic shaker at 340 
C. Slices Were rinsed With 15 mL of fresh buffer and incu 
bated for an additional 30 minutes in fresh buffer containing 
0.1 uM [3H]DA (6 slices/3 ml). Subsequently, slices Were 
rinsed With 15 ml of fresh buffer and transferred to a glass 
superfusion chamber. Slices Were superfused(1.0 ml/min) for 
60 minutes With Krebs buffer containing nomifensine (10 
11M) and pargyline (10 11M) and maintained at 340 C., pH 7.4, 
With continual aeration (95% O2/ 5% CO2). TWo ?ve minute 
samples (5 ml each) Were collected to determine basal out 
?oW of [3H]DA. bis-Alkyl pyridino analogs Were added to the 
superfusion buffer after the collection of the second sample 
and remained in the buffer until 12 consecutive ?ve minute 
samples Were collected. Subsequently, S-(—)-nicotine (10 
11M) Was added to the buffer and an additional 12 consecutive 
?ve minute samples Were collected. At the end of the experi 
ment, each slice Was solubiliZed and the [3H] content of the 
tissue determined. 
Radioactivity in the superfusate and tissue samples Was 
determined by liquid scintillation spectroscopy. Fractional 
release for tritium collected in each sample Was divided by the 
total tritium present in the tissue at the time of sample collec 
tion and Was expressed as a percentage of total tritium. Basal 
[3H]out?oW Was calculated from the average of the tritium 
collected in the tWo ?ve minute samples just before addition 
of the bis-alkyl pyridino analog. The sum of the increase in 
collected tritium resulting from either exposure to the test 
compound or exposure to S-(—)-nicotine in the absence and 
presence of the test compound equaled total [3H]over?oW. 
[3H]Over?oW Was calculated by subtracting the [3H]out?oW 
during an equivalent period of prestimulation from the values 
in samples collected during and after drug exposure. Inas 
much as the radiolabelled compounds Were not separated and 
identi?ed, the tritium collected in superfusate is referred to as 
either [3H]out?oW or [3H]over?oW, rather than as [3H]DA. 
[3 H]Over?oW primarily represents [3 H]DA in the presence of 
nomifensine and pargyline in the superfusion buffer. 
The bis-alkyl pyridino analogs Were evaluated for their 
ability to evoke [3H]DA release from rat striatal slices. In 
addition, the classical competitive nicotinic antagonist DHBE 
Was also examined in this assay for comparison. None of the 
compounds examined had any signi?cant [3H]DA releasing 
properties in this assay in the concentration range tested. 
Since striatal nicotine-evoked [3H]DA release is thought to be 
mediated through a mechanism involving the (1362* receptor 
subtype, these compounds do not possess signi?cant agonist 
activity at the 0662* subtype. 
The bis-alkyl pyridino analogs Were also evaluated for 
their ability to inhibit nicotine-evoked [3H]DA release. In 
these experiments, the striatal slices Were superfused for 60 
minutes With various concentrations of the analogs prior to 
nicotine (10 11M) exposure. Antagonist activity Was evaluated 
by comparing the nicotine-evoked [3H]over?oW in the 
absence and presence of the analogs. The relative order of 
potency of the bis-alkyl pyridino analogs for inhibition of 
nicotine-evoked [3H] DA release from rat striatal slices is 
illustrated in Table 3 by a comparison of their IC5O values. 
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TABLE 3 
Comparative IC5Os for bis-Alkyl Pyridino Analogs in the S-(—) 
nicotine-evoked [3H]DA Release Assay 
Compound IC5O (11M) 
NONI 0.62 
NDNI >100 
DH[5E 1.0 
bPPeI NDZ’ 
bPHxI ND 
bPOI >1.0" 
bPNB ND 
bPDI >1.0" 
bPUB ND 
bPDDB 1.0 
bPHxI ND 
bPiOI ND 
bPiNB ND 
bPiDI ND 
bPiUB ND 
bPiDDB 0.002 
bQHxI ND 
bQOI ND 
bQNB ND 
bQDI ND 
bQUB ND 
bQDDB 0.020 
bIQHxI ND 
bIQOI ND 
bIQNB ND 
bIQDI ND 
bIQUB ND 
bIQDDB ND 
bNHxI ND 
bNOI ND 
bNNB ND 
bNDI ND 
bNUB ND 
bNDDB 4.37 
“Compunds only tested for two concentration points 0.1 and 1.0 pM 
bND = Not Determined 
Example 34 
Compounds 1-3 (FIG. 3) were prepared by reacting S-(—) 
nicotine with the appropriate n-alkyl iodide in glacial acetic 
acid, utilizing the procedure described by Crooks, et al., Drug 
Dev. Res. 1995, 36, 91-102. The N-n-alkylpyridinium salts 
4-7 (FIG. 3) were obtained via n-alkylation of pyridine with 
the appropriate n-alkyl halide. The conformationally 
restricted racemic syn- and anti-nicotine analogs 8-12 and 
13-17, respectively (FIG. 3), were prepared via regiospeci?c 
alkylation of the pyridine-N atom of the corresponding free 
base. The syn-free base was synthesized from 7-aza-1-tetral 
one, and the anti-free base was prepared from 5-aza-1-tetral 
one. N,N'-Dodecanediyl-bis-nicotinium dibromide, 18 (FIG. 
4), was prepared by dissolving S-(—)-nicotine in glacial acetic 
acid, stirring the mixture for ?ve minutes and then adding 
dibromododecane. The solution was stirred under re?ux for 
three days, the solvent was evaporated under reduced pres 
sure, and the resulting residue was treated with an aqueous 
saturated solution of NaHCO3. The resulting mixture was 
then extracted with diethyl ether (3x50 mL), and then with 
chloroform (3x50 mL). The aqueous layer was collected and 
lyophilized for 24 hours, and the resulting solid was triturated 
with chloroform. After ?ltration, the ?ltrate was dried over 
anhydrous MgSO4 and removal of solvent afforded the bis 
nicotinium salt, 18. N,N'-Dodecanediyl-bis-pyridinium 
dibromide, 19 (FIG. 4) was prepared by reacting an excess of 
pyridine with dibromododecane for 24 hours at 65° C. in the 
absence of solvent. The resulting solid was collected by ?l 
tration, dissolved in water, and the aqueous solution washed 
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with diethyl ether (3x50 mL). The aqueous solution was then 
lyophilized to afford 19 as a crystalline solid. 
All compounds were characterized by 1H and 13 C NMR 
spectroscopy, mass spectroscopy and elemental analysis. 
Biological Assays 
Subjects. 
Male Sprague-Dawley rats (225-250 g) were obtained 
from Harlan Industries (Indianapolis, Ind.) and housed two 
per cage with free access to food and water in the Division of 
Lab Animal Resources in the College of Pharmacy at the 
University of Kentucky. All experiments were carried out in 
accordance with the 1996 NIH Guide for the Care and Use of 
Laboratory Animals and were approved by the Institutional 
Animal Care and Use Committee at the University of Ken 
tucky. 
[3H]-Dopamine Over?ow from Superfused Striatal Slices. 
[3H]-Dopamine release assays were performed according 
to Dwoskin, L. P., and Zahniser, N. R., .1. Pharmacol. Exp. 
Then 1986, 239, 442; Miller, D. K., et al., J. Pharmacol. Exp. 
Ther 2002, 302, 1113; Reuben, M., Clarke, P. B., Neurophar 
macology 2000, 39, 290, with minor modi?cations. Striatal 
coronal slices (500 um, 4-6 mg) were obtained and incubated 
for 30 minutes in Krebs’ buffer (in mM: 118 NaCl, 4.7 KCl, 
1.2 MgCl2, 1 NaH2PO4, 1.3 CaCl2, 11.1 glucose, 25 
NaHCO3, 0.11 L-ascorbic acid and 0.004 disodium EDTA, 
pH 7.4, saturated with 95% O2/5% CO2) in a metabolic 
shaker at 34° C. Slices were incubated with 0.1 uM (?nal 
concentration) of [3 H]-dopamine during the latter 30 minutes 
of the 60-minute incubation period. Each slice was trans 
ferred to a glass superfusion chamber maintained at 34° C. 
and superfused (1 ml/min) with Krebs’ buffer containing 
nomifensine (10 uM) and pargyline (10 uM) to inhibit [3H] 
dopamine reuptake after release into the extracellular space, 
ensuring that [3H]-over?ow primarily represented [3H] 
dopamine. Sample collection (5 -minute; 5 mL) began after 60 
minutes of superfusion. The ability of N-n-alkylated nico 
tinium, N-n-alkylated pyridinium, conformationally 
restricted N-n-alkylated nicotinium and bis-azaaromatic qua 
ternary ammonium analogs to evoke [3H]-dopamine release 
(intrinsic activity) and to inhibit nicotine-evoked [3H] 
dopamine release (act as antagonists) were determined. At the 
end of the experiment, each slice was solubilized, and the 
[3H]-content of the tissue determined. Release during each 
minute was normalized for total tissue [3 H] -content. Analog 
induced intrinsic activity and inhibitory activity were deter 
mined using slices from the same rat (repeated-measures 
design). 
The amount of [3H] in each sample was calculated by 
dividing the total [3H] collected in each sample by the total in 
the tissue at the time of sample collection (de?ned as frac 
tional release). The sum of all the increases in [3H]-dopamine 
fractional release resulting from either exposure to analog or 
nicotine equaled “total over?ow”. “Over?ow,” rather than 
“release,” is the more correct terminology because the neu 
rotransmitter measured is the net result of release and 
reuptake. Data were analyzed by weighted, least squares 
regression analysis of the sigmoidal concentration-effect 
curves to obtain EC5O and IC5O values. 
[3H]-Nicotine ((>t4[32* Subtype) and [3H]-Methyllycac 
onitine (00* Subtype) Binding Assays. 
Whole brain, excluding cortex and cerebellum, was 
homogenized in 20 ml of ice-cold buffer, containing (in mM): 
2 HEPES, 11.8 NaCl, 0.48 KCl, 0.25 CaCl2 and 0.12 MgSO4, 
pH 7.5. Homogenate was centrifuged (25,000 g, 15 minutes, 
40 C.). Pellets were resuspended in 20 ml of buffer and incu 
bated at 37° C., for ten minutes, cooled to 4° C. and centri 
fuged (25,000 g, 15 minutes, 4° C.). Pellets were resuspended 
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and centrifuged using the same conditions. Final pellets were 
stored in assay buffer, containing (in mM): 20 HEPES, 118 
NaCl, 4.8 KCl, 2.5 CaCl2, and 1.2 MgSO4) pH 7.5 at —700 C. 
Upon use, ?nal pellets were resuspended in ~20 ml assay 
buffer. Samples (250 pl) contained 100-140 ug of membrane 
protein, 3 nM [3H]-nicotine or 3 nM [3H]-methyllycac 
onitine, and analog (0.1 uM-l mM) in assay buffer containing 
50 mM Tris. Control was in the absence of analog. In [3H] 
nicotine and [3H]-methyllycaconitine binding assays, non 
speci?c binding was determined in the presence of 10 uM 
nicotine, and 10 uM methylycaconitine, respectively. Incu 
bations proceeded for 60 minutes at room temperature using 
96-well plates and were terminated by harvesting on Uni?l 
ter-96 GF/B ?lter plates presoaked in 0.5% polyethylen 
imine, using a Packard FilterMate harvester. 
After washing ?ve times with 350 pl ice-cold assay buffer, 
?lter plates were dried (60 minutes, 490 C.), bottom-sealed, 
and ?lled with Packard’s MicroScint 20 cocktail (40 ul/well). 
After 60 minutes, ?lter plates were top-sealed, and radioac 
tivity determined using a Packard TopCount. Protein concen 
trations were determined using bovine serum albumin as the 
standard. 
Blood-Brain Barrier Choline Transporter Af?nity Assays. 
Quaternary ammonium analogs were evaluated for their 
ability to inhibit [3 H] -choline uptake into brain providing an 
indication of the ability of these analogs to interact with the 
choline transporter. These assays were conducted using the in 
situ rat brain perfusion method of Takasato, et al., Am. J. 
Physiol. 1984, 247, 484, as modi?ed by Allen and Smith, J. 
Neurochem, 2001, 76, 1032. Inhibition coef?cients (Ki, con 
centration of analog inhibiting 50% of [3H]-choline uptake 
into brain) were determined using a single inhibitor concen 
tration as described by Smith, et al., .1. Neurochem, 1987, 49, 
1651. K- values were compared by ANOVA followed by 
Bonferoni’s multiple comparisons test to determine if an 
analog inhibits [3H]-choline uptake. 
TABLE 4 
Evaluation of N-n-alkylnicotinium analogs at native nAChRs. 
Nicotine-evoked [3H]Nicotine [3H]MLA 
[3H]DA Over?ow Binding Binding 
Compound 1050 M“ K,- pMb K,- uMb 
NONI 0.62 (0.20-1.9) 20 (15-25) 12 (9.2-16) 
NDNI na 0.09 (0.08-0.11) na 
NDDNI 0.009 (0.003-0.03) 0.14 (0.11-0.17) na 
“Values are means of three to ten independent experiments, 95% con?dence interval is given 
in parentheses (na = not active). 
“Values are means of four to ten independent experiments, 95% con?dence interval is given 
in parentheses (na = not active). 
Example 35 
Simple N-n-alkylpyridiniums, with alkyl chain lengths 
ranging from C1 to C20, exhibit moderate to low af?nity for 
nAChR subtypes mediating nicotine-evoked DA release and 
for (x4[32* nAChRs (IC5O:90-530 nM and Ki:9-44 uM, 
respectively; Table 5). These compounds also lack al?nity for 
(>t7* nAChRs. These data demonstrate the importance of the 
3-(2'-pyrrolidino) moiety in the N-n-alkylnicotinium series of 
compounds for potent inhibition of nAChR subtypes mediat 
ing nicotine-evoked dopamine release. 
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TABLE 5 
Inhibitory activity of simple N-n-alkylpyridinium analogs at native 
nAChRs. 
Nicotine-evoked [3H]Nicotine [3H]MLA 
[3H]DA Over?ow Binding Binding 
Compound 1050 uM" K,- M!’ K,- M!’ 
NDPI 0.13 (0.02-0.87) 17 (14-20) na 
NDDPI 0.26 (0.02-4.23) na na 
NPDPB 0.32 (0.11-0.87) 38 (28-51) na 
NEcPB 0.12 (0.01-2.38) na na 
“Values are means of ?ve to six independent experiments, 95% con?dence interval is given 
in parentheses. 
alues are means of four independent experiments, 95% con?dence interval is given in 
parentheses (na = not active.) 
Example 36 
The nAChR receptor properties of some conformationally 
restricted analogs of the above N-n-alkylnicotinium com 
pounds are shown in Table 6. These analogs were designed to 
assess the rotameric preference about the C3-C2‘ bond of 
NONI and NDNI for interaction with nAChR subtypes. Two 
classes of bridged nicotinium analogs, representing extreme 
rotameric conformations (i.e. syn- and anti-rotamers, FIG. 3) 
were examined. Interestingly, these conformationally 
restrained analogs lacked al?nity for (x4[32* and (>t7* 
nAChRs, as determined from [3H]-nicotine and [3H]-meth 
yllycaconitine binding assays. In addition, with the exception 
of BCDD, these analogs potently and selectively inhibited 
nicotine-evoked [3H]-dopamine release (IC5O values 30-660 
nM), although no clearly de?ned structure-activity trends 
could be determined. These analogs may be interacting with 
multiple nAChR subtypes mediating nicotine-evoked 
dopamine release. Alternatively the lack of structure-activity 
relationships within this group may be due to the fact that 
these molecules are racemic in nature. It is conceivable that 
the optical isomers of each compound may exhibit different 
al?nities at the nAChR subtypes examined, thus confounding 
the structural analysis. 
TABLE 6 
Inhibitory activity of simple N-n-alkylpyridinium analogs at native 
nAChRs 
Nicotine-evoked 
[3H]DA Over?ow [3H]Nicotine [3H]MLA 
Compound IC5O uM“ Bindingl7 Bindingl7 
ACO 0.08 (10.04) na na 
ACN 0.66 (10.03) na na 
ACD 0.58 (10.55) na na 
ACU 0.04 (10.02) na na 
ACDD 0.22 (10.15) na na 
BCO 0.04 (10.02) na na 
BCN 0.31 (10.01) na na 
BCD 0.03 (10.03) na na 
BCU 0.04 (10.03) na na 
BCDD na na na 
“Values are means of six to eight independent experiments for the DA release assay, standard 
error is given in parentheses (na = not active). 
etermined at a single 10 M concentration in four independent experiments. 
Example 37 
The bis-aZaaromatic quaternary ammonium analogs: 
N,N'-dodecanediyl-bis-nicotinium dibromide (18, FIG. 4), 
and N,N'-dodecanediyl-bis-pyridinium dibromide (19, FIG. 
4), were synthesiZed and evaluated for their inhibitory prop 
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erties at nAChR subtypes (Table 7). C 1 2 analogs Were studied, 
based on our ?ndings that the C12 analog (NDDNI) in the 
N-n-alkylnicotinium series Was the most potent as an inhibi 
tor of the nAChR subtype mediating nicotine-evoked [3H] 
dopamine over?ow. These compounds Were not potent or 
selective for the subtype mediating nicotine-evoked dopam 
ine release. 
TABLE 7 
Inhibitory activity of N,N'—bis—azaaromatic quaternary ammonium 
C‘7 analogs bNDDB and bPDDB at native nAChRs. 
Nicotine-evoked [3H]Nicotine [3H]MLA 
[3H]DA Over?ow Binding Binding 
Compound r050 uM" K,- M!’ K,- uMb 
bNDDB 0.17 (10.13) 1.95 (10.19) na 
bPDDB 1.00 (10.38) 9.15 (10.17) 33 (14.6) 
“Values are means of four to six experiments, standard error is given in parentheses. 
bValues are means of three to four experiments, standard error is given in parentheses (na = 
not active). 
Example 38 
Analog Af?nity for, and Transport by, the 
Blood-Brain Barrier Choline Transporter 
Several N-n-alkylnicotinium analogs have been shoWn to 
have good a?inity for the blood-brain barrier choline trans 
porter. Speci?cally, NONI, inhibits [3H]-choline uptake 
(Table 8) With an apparent K- value of 49 uM (124 uM). The 
C 1 analog, NMNI, shoWs loW af?nity for the transporter, With 
an apparent K- value of greater than 1000 uM. The C1O analog, 
NDNI, inhibits [3H]-choline uptake into brain With an appar 
ent Kl. value of 27 uM (12 uM), similar to NONI and choline. 
The C4 analog, NBNI, has an apparent K- value of 7771588 
uM. These results demonstrate that increasing the length of 
the N-n-alkyl chain in these N-n-alkylnicotinium analogs 
facilitates transporter binding, and thus, enhances brain 
uptake via the blood-brain barrier choline transporter. 
TABLE 8 
Af?nity of N-n-alkylcholine analogs and N-n-alkylnicotinium analogs 
for the blood brain barrier choline transporter. 
Concentration 
Compound 11M” Ki 11M” 
N-n-Octylcholine 10 1.7 (10.3) 
N-n-Hexylcholine 10 2.2 (10.1) 
N-n-Octylpyridinium iodide 250 32 (122) 
NBNI 250 777 (1590) 
NONI 250 49 (124) 
NDNI 250 27 (10.1) 
“Values are means of three to ?ve independent experiments, standard error is given in 
parentheses. 
In vitro therapeutic index (ICSO cytotoxicity/ICSO complement inhibition) 
Example 39 
[3H]-NONI Brain Uptake 
Considering the above Kl. value for NONI, experiments 
Were performed to verify that this compound gains access to 
brain via the blood-brain barrier choline transporter. Thus, 
brain distribution parameters of [3H]-NONI Were deter 
mined. Uptake of [3H]-NONI (1 uCi/ml) into rat brain Was 
evaluated from 0-60 seconds in the absence of unlabeled 
NONI. The transfer coe?icient value (Kl-n) for [3H]-NONI 
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uptake Was 1.5910.14><10_3 ml/s/g, calculated from the slope 
of the compound accumulating in brain versus time. An 
uptake time of 45 seconds Was chosen as Within the linear 
portion of the brain uptake curve in order to evaluate [3H] 
NONI brain uptake in the presence of unlabeled NONI. Unla 
beled NONI (250 uM) in the perfusion ?uid resulted in 46% 
inhibition of [3H]-NONI brain uptake, suggesting saturable 
kinetic parameters associated With NONI transport into brain. 
The ability of choline to inhibit [3H]-NONI uptake into 
brain and [3 H] -NONI distribution parameters Were also deter 
mined. The permeability-surface area product (PA; ml/s/g) 
for [3H]-NONI With no inhibitors present Was 1.6410.37>< 
10'3 ml/ s/ g, determined as a single time point PA value. If 
NONI is transported in total, or in part, by the blood-brain 
barrier choline transporter, then addition of choline to the 
perfusion ?uid should reduce brain uptake of [3H]-NONI. 
When 500 uM choline Was added to the perfusion ?uid the PA 
for [3H]-NONI decreased ~25% to 1.2410.5><10_3 ml/s/g. A 
higher concentration (5 mM) of choline further reduced the 
uptake of [3H]-NONI to 7.5513.30><104 ml/s/g, Which Was 
<50% of the uptake in the absence of choline. These results 
demonstrate that a signi?cant component of NONI uptake 
occurs via the blood-brain barrier choline transporter. 
Example 40 
N-n-Alkylpicolinium analogs shoWn in FIG. 5 Were pre 
pared by reacting 3-picoline With the appropriate n-alkyl 
iodide utiliZing conditions described in Crooks, et al., Drug 
Dev. Res. 1995, 36, 91. The N,N'-alkyl-bis-picolinium ana 
logs shoWn in FIG. 5 Were prepared by reacting an excess of 
3-picoline With a variety of diiodo- or dibromoalkanes for 24 
hours in the absence of solvent. The resulting solid Was col 
lected by ?ltration, dissolved in Water and the aqueous solu 
tion Was Washed With diethyl ether (3x50 mL). The aqueous 
solution Was then lyophiliZed to afford either a solid or vis 
cous hygroscopic oil. All compounds Were characterized by 
1H and 13 C NMR spectroscopy, mass spectroscopy and 
elemental analysis. 
Biological Assays: 
Male Sprague-DaWley rats (225-250 g) Were obtained 
from Harlan Industries (Indianapolis, Ind.) and housed tWo 
per cage With free access to food and Water in the Division of 
Lab Animal Resources in the College of Pharmacy at the 
University of Kentucky. All experiments Were carried out in 
accordance With the 1996 NIH Guide for the Care and Use of 
Laboratory Animals and Were approved by the Institutional 
Animal Care and Use Committee at the University of Ken 
tucky. 
[3H]DA release assays Were performed according to pre 
viously published methods With minor modi?cations. Striatal 
slices (500 um, 4-6 mg) Were incubated for 30 minutes in 
Krebs’ buffer (in mM: 118 NaCl, 4.7 KCl, 1.2 MgCl2, 1 
NaH2PO4, 1.3 CaCl2, 11.1 glucose, 25 NaHCO3, 0.11 
L-ascorbic acid and 0.004 disodium EDTA, pH 7.4, saturated 
With 95% O2/5% CO2) in a metabolic shaker at 34° C. Slices 
Were incubated With 0.1 uM (?nal concentration) [3 H] DA 
during the latter 30 minutes of the 60-minute incubation 
period. Each slice Was transferred to a glass superfusion 
chamber maintained at 34° C. and superfused (1 ml/min) With 
Krebs’ buffer containing nomifensine (10 uM) and pargyline 
(10 uM) to inhibit [3H]DA reuptake and metabolism, respec 
tively, after release into the extracellular space, ensuring that 
[3H]over?oW primarily represents [3H]DA. Sample collec 
tion (5-minute; 5 ml) began after 60 minutes of superfusion. 
The ability of N-n-alkylpicolinium and N,N'-alkyl-bis-pi 
colinium analogs to evoke [3 H] DA release (i.e., exhibit intrin 
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sic activity) and to inhibit nicotine-evoked [3H]DA release 
(i.e., act as nAChR antagonists) were determined. To estab 
lish that these analogs act as nAChR antagonists, by de?ni 
tion, inhibition of the response to nicotine must be observed at 
analog concentrations that do not evoke a response. Thus, the 
ability of these analogs to elicit intrinsic activity (evoke [3 H] 
DA over?ow) was determined. At the end of the experiment, 
each slice was solubiliZed and [3H]content of the tissue deter 
mined. Release during each minute was normaliZed for total 
[3 H] content of the slice. Analog-induced intrinsic activity and 
inhibitory activity were determined using slices from the 
same rat (repeated-measures design). 
Fractional release was calculated by dividing the total tri 
tium collected in each sample by the total tritium in the tissue 
at the time of sample collection. The sum of all the increases 
in [3 H]DA fractional release resulting from either exposure to 
analog or nicotine equaled “total [H]DA over?ow”. “Over 
?ow,” rather than “release,” is the more correct terminology 
because the neurotransmitter measured is the net result of 
release and reuptake. Typically, data were analyZed by 
weighted, least squares regression analysis of sigmoidal con 
centration-effect curves to obtain EC5O and IC5O values. 
Interaction of the analogs with nAChR subtypes probed by 
[3H]nicotine binding (0462*) and [3H]MLA binding (00*) 
to rat brain membranes was determined to assess nAChR 
subtype selectivity of the analogs. [3H]Nicotine and [3 H] 
MLA binding assays were performed using whole brain, 
excluding cortex and cerebellum. Whole brain was homog 
eniZed in 20 ml of ice-cold buffer (in mM: 2 HEPES, 11.8 
NaCl, 0.48 KCl, 0.25 CaCl2, and 0.12 MgSO4, pH 7.5). 
Homogenates were centrifuged (25,000 g, 15 minutes, 40 C.). 
Pellets were resuspended in 20 ml of buffer and incubated at 
37° C., for 10 minutes, cooled to 40 C. and centrifuged (25, 
000 g, 15 minutes, 40 C.). Pellets were resuspended and 
centrifuged again using the same conditions. Final pellets 
were stored at —70° C. in assay buffer (in mM: 20 HEPES, 1 18 
NaCl, 4.8 KCl, 2.5 CaCl2, and 1.2 MgSO4, pH 7.5). Upon use, 
?nal pellets were resuspended in ~20 ml assay buffer. 
Samples (250 pl) contained 100-140 pg of membrane protein, 
3 nM [3H]nicotine or 3 nM [3H]MLA, and a range of con 
centrations (0.1 uM-l mM) of analog in assay buffer contain 
ing 50 mM Tris. Control was in the absence of analog. In 
[3H]nicotine and [3 H] MLA binding assays, nonspeci?c bind 
ing was determined in the presence of 10 uM nicotine and 10 
uM MLA, respectively. Incubation proceeded for 60 minutes 
at room temperature using 96-well plates and was terminated 
by harvesting on Uni?lter-96 GF/B ?lter plates, presoaked in 
0.5% polyethylenimine, using a Packard FiterMate harvester. 
After washing 5>< with 350 pl ice-cold assay buffer, ?lter 
plates were dried (60 minutes, 49° C.), bottom-sealed, and 
?lled with Packard’s MicroScint 20 cocktail (40 ul/well). 
After 60 minutes, ?lter plates were top-sealed, and radioac 
tivity determined. Protein concentration was determined 
using BSA as the standard. The results are shown in Table 9. 
TABLE 9 
Inhibitory activity of N-n-alkylpicoliniurn iodide analogs at 
native nAChRs. 
Nicotine-evoked [3H]Nicotine [3H]MLA 
[3H]DA Over?ow Binding Binding 
Compound 1c50 11M” K,- M!’ K,- 0M1’ 
NOPiI 1.0 (10.09) Na Na 
NNPiI nd 62 (117) Na 
NDPiI 0.3 (10.05) 26 (13.6) Na 
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TABLE 9-continued 
Inhibitory activity of N-n-alkylpicolinium iodide analogs at 
native nAChRs. 
Nicotine-evoked [3H]Nicotine [3H]MLA 
[3H]DA Over?ow Binding Binding 
Compound 1c50 11M” K,- M!’ K,- M!’ 
NUPiI nd Na Na 
NDDPiI 0.03 (10.02) Na Na 
“Values are means of three to ?ve independent experiments, standard error is given in 
parenthesis (nd = not determined). 
bValues are means of four independent experiments, standard error is given in parentheses 
(na = not active). 
Table 9 shows the inhibitory activity of the N-n-alkylpi 
colinium analogs with carbon chain lengths of CS-Cl2 in the 
nicotine-evoked [3H]DA over?ow assay and in the [3H]nico 
tine and [3H]MLA binding assays. This series of analogs was 
relatively selective for the nAChR subtype(s) mediating nico 
tine-evoked [3H]DA over?ow, in that, these analogs did not 
inhibit binding of either [3H]nicotine and [3 H] MLA to rat 
brain membranes, indicating low a?inity for or no interaction 
with 0462* and 00* nAChRs. 
In the nicotine-evoked [3H]DA over?ow assay, NDDPiI at 
concentrations of 21.0 uM evoked [3H]DA over?ow, and 
thus, exhibited intrinsic activity; whereas the C8 and C10 
analogs demonstrated no intrinsic activity up to 1.0 uM. As 
the carbon chain length was increased the inhibitory potency 
at nAChRs mediating nicotine-evoked [3 H] DA over?ow 
increased with a rank order of NDDPiI>NDPiI>NOPiI (Table 
9). The most potent analog in the series was NDDPiI 
(IC5O:30 nM). Furthermore, NDDPiI inhibited nicotine 
evoked [3H] DA over?ow by 63%, indicating that this analog 
may interact with a single subtype of nAChR that mediates 
this effect of nicotine. 
Table 10 illustrates the ability of a series of N,N'-bis-alky 
lpicolinium analogs with carbon chain lengths of C6-Cl2 to 
inhibit nicotine-evoked [3H]DA over?ow and the binding of 
[3H]nicotine and [3H]MLA to rat brain membranes. None of 
the analogs in this series inhibited either [3H]nicotine or 
[3H]MLA binding with high a?inity, indicating no a?inity at 
00,* nAChRs and only low a?inity at 0462* nAChRs. 
Furthermore, none of the N,N'-bis-alkylpicolinium ana 
logs in this series evoked [3H] DA over?ow, and thus, they did 
not exhibit intrinsic activity at subtypes mediating nicotine 
evoked DA release. The most active analogs in this series are 
those with the longer n-alkyl chain length and with an even 
number of carbon atoms (Table 10). bPiDDB (the C 1 2 analog) 
was the most potent (ICSOIS nM) inhibitor of the nAChR 
subtype mediating nicotine-evoked [3H] DA over?ow. 
bPiDDB is also selective for the nAChR subtype mediating 
nicotine-evoked [3 H] DA over?ow, since it has low or no 
a?inity for the 0462* and 00* nAChR subtypes (Table 10). 
Thus, bPiDDB is a selective inhibitor of the nAChR subtype 
that mediates nicotine-evoked [3H]DA over?ow. bPiDDB is 
approximately 320-fold more potent than DHBE in inhibiting 
nicotine-evoked [3 H] DA over?ow. bPiDDB and the other 
analogs in this series inhibited [3H]DA over?ow by a maxi 
mum of 60%, similar to the maximum inhibition observed for 
conotoxin-MII, suggesting that this small synthetic molecule 
(bPiDDB) and the neurotoxic Conus peptide of higher 
molecular weight may be acting at the same nAChR subtype 
to inhibit nicotine-evoked DA release. 
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TABLE 10 
Inhibitory activity of N,N'—bis—picolinium salts at native 
nAChRs. 
Nicotine-evoked [3H]Nicotine [3H]MLA 
[3H]DA Over?ow Binding Binding 
Compound 10,0 11M” K,- M!’ K,- 6M1’ 
bPiHxI 1.66 (20.85) Na Na 
bPiOI 0.01 (20.009) Na Na 
bPiNB 1.52 (20.34) 80 (217) Na 
bPiDI 0.03 (20.01) Na Na 
bPiUB 1.61 (21.08) 69 (229) Na 
bPiDDB 0.005 (20.003) 49 (217) Na 
“Values are means of four to six independent experiments, standard error is given in 
arenthesis. 
gValues are means of four independent experiments, standard error is given in parentheses 
(na = not active). 
The N,N'-dodecyl-bis-aZaaromatic analogs (i.e. the C 1 2 
analogs) were tested and compared for their inhibitory activ 
ity. The compounds tested included the dibromide salts of the 
C 1 2 analogs of bis-nicotinium (bNDDB), bis-pyridinium (bP 
DDB), bis-picolinium (bPiDDB), bis-quinolinium 
(bQDDB), and bis-isoquinolinium (bIQDDB). The results 
are shown in Table 11. 
TABLE 11 
Inhibitorv activity of the C‘? N N'—bis-AZaaromatic analogs. 
Nicotine 
evoked 
Over?ow Uptake Binding Binding 
Compound ICSO (11M) K.- (HM) K.- (PM) K.- (11M) 
bNDDB 0.04 2 0.02 43.2 214.9 1.95 2 0.19 >100 
bPDDB 1.00 2 0.38 >100 9.15 2 0.17 33 2 4.6 
bPiDDB 0.005 2 0.003 >100 48.6 2 17.2 >100 
bQDDB 0.0212001 3.86 20.22 >100 1.612021 
bIQDDB 0.007 2 0.003 0.27 2 0.07 6.10 2 0.73 2.21 2 0.25 
bPiDDB has 4-5 orders of magnitude higher af?nity for the nAChR subtype mediating 
nicotine-evoked [3H] DA over?ow compared to its af?.nity at both 014 [542* and 017* nAChRs. 
Thus, based on the preclinical data, by inhibiting dopamine release bPiDDB and related 
analogs should diminish the rewarding effects produced by nicotine self-administration and 
serve as tobacco use cessation agents. 
What is claimed is: 
1. A method of treating a dopamine mediated disease state 
comprising administering to an individual in need thereof an 
effective amount of a composition comprising at least one 
nicotine antagonist having the formula 
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wherein: 
Rings 1 and 2 are pyridinium; 
R2, R3, R4, R5, R6 are each independently selected from 
hydrogen; alkyl; and substituted alkyl; 
R1 is selected from alkyl, substituted alkyl, cycloalkyl, 
substituted cycloalkyl, alkenyl, substituted alkenyl, 
alkynyl, substituted alkynyl, aryl, substituted aryl, 
arylalkyl, substituted arylalkyl, arylalkenyl, substi 
tuted arylalkenyl, arylalkynyl, substituted arylalky 
nyl, heterocyclic, substituted heterocyclic, alkoxy, 
alkylamine, thioalkyl; and 
X is selected from Cl, Br, I, HSO4, 1/2SO2, CH3SO3, 
p-TsO, CF3SO3 and any ion that completes the salt 
form of the nicotine antagonist; and enantomers, dias 
tereomers and racemic mixes thereof, 
wherein the nicotine antagonist binds to nAChR and inhib 
its release of dopamine. 
2. The method of claim 1 wherein the dopamine mediated 
disease state is selected from the group consisting of myas 
thenia gravis, Parkinson’s disease, Alzheimer’s disease, 
schizophrenia, eating disorders, and drug addiction. 
3. The method of claim 2 wherein said drug addiction is to 
a drug selected from the group consisting of nicotinic ago 
nists, cocaine, amphetamines, caffeine, phencyclidine, opi 
ates, barbituates, benZodiaZepines, cannabinoids, hallucino 
gens and alcohol. 
4. The method of claim 2 wherein the composition is 
administered orally, transdermally, transnasally, rectally, sub 
linguinally, subdermally, intraocularly or via smokeless inha 
lation. 
5. A method of treating drug addiction in a patient com 
prising administering to the patient an effective amount of a 
composition comprising at least one nicotine antagonist hav 
ing the formula 
wherein: 
Rings 1 and 2 are pyridinium; 
R2, R3 , R4, R5 , R6 are each independently selected from 
hydrogen; alkyl and substituted alkyl; 
R1 is selected from alkyl, substituted alkyl, cycloalkyl, 
substituted cycloalkyl, alkenyl, substituted alkenyl, 
alkynyl, substituted alkynyl, aryl, substituted aryl, 
arylalkyl, substituted arylalkyl, arylalkenyl, substi 
tuted arylalkenyl, arylalkynyl, substituted arylalky 
nyl, heterocyclic, substituted heterocyclic, alkoxy, 
alkylamine, thioalkyl; and 
X is selected from Cl, Br, I, HSO4, 1/2SO2, CH3SO3, 
p-TsO, CF3SO3 and any ion that completes the salt 
form of the nicotine antagonist; and enantomers, dias 
tereomers and racemic mixes thereof, 

